

Scientific Posters

ARV-based Prevention – Vertical transmission

P001	<p>Postnatal prophylaxis among infants born to women living with HIV in England, 2018-2022 <i>Emily Dema, Rebecca Sconza, Helen Peters, Alasdair Bamford, Hermione Lyall, Kate Francis, Claire Thorne (London, UK)</i></p>
P002	<p>Outcomes following prenatal exposure to DTG-containing antiretroviral therapy regimens: data from the DOLOMITE-EPPICC study <i>Rebecca Sconza, Georgina Fernandes, Heather Bailey, Karoline Aebi-Popp, Luminita Ene, Marco Florida, Anna Maria Gamell, Marta Illán Ramos, Helen Peters, Anna Samarina, Leigh Ragone, Vani Vannappagari, Claire Thorne (London, UK)</i></p>
P003	<p>Antiretroviral therapy in pregnancy in England in 2019-2022: common regimens and treatment modifications <i>Rebecca Sconza, Helen Peters, Laurette L Bukasa, Laura Byrne, Alasdair Bamford, Hermione Lyall, Graham P. Taylor, Claire Thorne (London, UK)</i></p>
P004	<p>HIV treatment cascade among pregnant women with pre-conception diagnosis: 2017-2022 <i>Helen Peters, Rebecca Sconza, Kate Francis, Laura Byrne, Claire Thorne (London, UK)</i></p>
P005	<p>The peripartum viral load cascade and outcomes of infants exposed to HIV in Lesotho <i>Kathrin Haenggi, Moleboheng Mokebe, Lipontso Motaboli, Makobefo Chakela, Mpho Kao, Mathebe Kopo, Irene Ayakaka, Monrongoe Nyakane, Tapiwa Tarumbiswa, <u>Niklaus Daniel Labhardt</u>, Jennifer Anne Brown, Nadine Tschumi (Basel, Switzerland)</i></p>
P006	<p>Late or missed HIV diagnosis during pregnancy is still occurring in a high-income country and represents a high risk of MTCT <i>Carmela Pinnetti, Cristina Marelli, Alice Ranzani, Valentina Mazzotta, Lucia Taramasso, Oscar Cirioni, Andrea Costantini, Barbara Menzaghi, Rosa Fontana Del Vecchio, Enrico Girardi, Annalisa Saracino, Antonella Cingolani, Antonio Di Biagio, Antonella d'Arminio Monforte, Andrea Antinori (Rome, Italy)</i></p>
P007	<p>The experience of pregnancy in women living with HIV (WLWH) between 2000 and 2023: a single-centre retrospective observational analysis <i>Sara Giovanna De Maria, Raffaella Marocco, Alessandra Grimaldi, Sara Corazza, Andrea Gasperin, Paola Zuccalà, Cosmo Del Borgo, Valeria Belvisi, Tiziana Tieghi, Miriam Lichtner (Rome, Italy)</i></p>
P008	<p>A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE-NEAT ID Network study <i>Justyna Kowalska, Sergii Antoniak, Lambert Assoumou, Anton Pozniak, Tetiana Rybak, Stephane De Wit, Ana Milinkovic, Sherie Roedling, Carl Fletcher, Leigh Ragone, Claire Thorne, Vani Vannappagari (Warsaw, Poland)</i></p>

ARV-based Prevention – PEP

P009 Virtual	<p>Management of reported side effects to PrEP: high rates of retention on PrEP after switching to a different F/TDF generic brand <i>Nicolo Girometti, Frances Lander, Elizabeth Ridsdill Smith, Hasan Mirza, Sheena McCormack, Victoria Tittle (London, UK)</i></p>
P010	<p>Analysis of occupational accidents involving exposure to biological fluids in a Portuguese peripheral hospital: implementation and efficacy of post-exposure prophylaxis <i>Clara Batista, Rita Pinto, Frederico Duarte, Ricardo C. Abreu, Sofia Jordão (Porto, Portugal)</i></p>

Scientific Posters

ARV-based Prevention – PrEP

P011	<p>Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre-exposure prophylaxis in Europe: the PrEPaRe study <i>Valentina Cambiano, Tina Bruun, <u>Marie Louise Jakobsen</u>, Ann Sullivan, Andrew Phillips (Copenhagen, Denmark)</i></p>
P012	<p>PrEP cascade improvement through same-day PrEP initiation <i><u>Kevin Woodward</u>, Timothy Guimond, Hommood Alrowais, Victor Monroy, Olivia Gemmell (Hamilton, Canada)</i></p>
P013	<p>HIV-1 prevalence and pre-exposure prophylaxis uptake among key populations in high-income economies (2017-2023): a systematic review and meta-analysis of real-world studies <i><u>Li Tao</u>, Xiwen Huang, Juan Yang, Jesse Najarro Cermeño, Soodi Navadeh, Julianna Catania, Kylie Scott, Sophie Schoeni, Dylan Mezzio (Foster City, CA, USA)</i></p>
P014	<p>Preparing for long-acting PrEP delivery: provider preferences for the provision of long-acting PrEP differ between MSM and heterosexual individuals in Europe <i>Hanne Zimmermann, Haoyi Wang, Johann Kolstee, Alejandro Adriaque Lozano, Melanie Schroeder, Ama Appiah, Ana Milinkovic, Supriya Sakar, Kai Jonas (Maastricht, Netherlands)</i></p>
P015	<p>Intention to use long-acting PrEP among 4960 heterosexual women and men in 20 European countries: results from the PROTECT survey <i><u>Kai Jonas</u>, Haoyi Wang, Hanne Zimmermann, Alejandro Adriaque Lozano, Melanie Schroeder, Ama Appiah, Ana Milinkovic, Supriya Sakar, Johann Kolstee (Maastricht, Netherlands)</i></p>
P016	<p>Low uptake of mpox and HPV vaccination among PrEP users in Switzerland <i><u>Benjamin Hampel</u>, Andrea Farnham, Celine Capelli, Enos Bernasconi, Dominique L. Braun, Alexandra Calmy, Julia Notter, Marcel Stoeckle, Bernard Surial, Vanessa Christinet, Katharine E. A. Darling, Manuela Rasi, Claudia Bernardini, David Haerry, Florian Vock, Nicola Low, Jan S. Fehr (Zurich, Switzerland)</i></p>
P017	<p>Recurrence of sexually transmitted infections is commonly found in a sub-population of Austrian PrEP users <i><u>Nikolaus Urban</u>, Thomas Neidhart, Katharina Grabmeier-Pfistershammer, Kaspar Laurenz Schmidt, Veronique Touzeau-Roemer, Nathalie Judith Auer, Robert Strassl, Wolfgang Weninger, Birgit Willinger, Wolfgang Michael Bauer, David Chromy (Vienna, Austria)</i></p>
P018 Virtual	<p>Effects of bariatric surgery on intracellular tenofovir-diphosphate levels in patients taking HIV pre-exposure prophylaxis <i><u>Matthew McGarrity</u>, Paul MacPherson, Abby Li, Mark Naccarato, Peter Anderson, Darrell Tan (Toronto, Canada)</i></p>
P019 Virtual	<p>Barriers and facilitators to pre-exposure prophylaxis (PrEP) uptake in England: experiences of people newly diagnosed with recently acquired HIV <i><u>Carina Hoerst</u>, Hannah Kitt, Dolores Mullen, Helen Corkin, Clare Humphreys, Ammi Shah, Vicky Gilbert, Adamma Aghaizu (London, UK)</i></p>
P020	<p>Changing unmet HIV PrEP need among men who have sex with men in London: an analysis of community cross-sectional surveys prior to and following routine HIV PrEP implementation in England <i><u>Flavien Coukan</u>, Dana Ogaz, Gary Murphy, Hamish Mohammed, John Saunders, Fiona Burns (London, UK)</i></p>

Scientific Posters

ARV-based Prevention – PrEP (continued)

P021 Virtual	<p>Chlamydia trachomatis serovars involved in lymphogranuloma venereum infections of men who have sex with men (MSM) and transgender women (TGW) in Buenos Aires, Argentina</p> <p><i>Luciana Spadaccini, Martin Vacchino, Maria Ines Figueroa, Gissella Mernies, Agustin Nava, Carolina Perez, Diego Salusso, Maria Victoria Iannantuono, Jonathan Garcia, Carina Cesar, Valeria Fink, Zulma Ortiz, Patricia Galarza, Pedro Cahn (Buenos Aires, Argentina)</i></p>
P022	<p>HIV pre-exposure prophylaxis (PrEP) failures in a large observational cohort from Poland with expansion of A6 subtype transmissions</p> <p><i>Bartosz Szetela, Karol Serwin, Aleksander Zinzuk, Lukasz Lapinski, Aleksandra Szymczak, Kamila Zielinska, Mateusz Bozejko, Anna Urbanska, Jacek Gasiorowski, Milosz Parczewski (Wroclaw, Poland)</i></p>
P023	<p>Addressing the unmet HIV prevention needs of women who have migrated from sub-Saharan Africa in France: an urgent call for PrEP integration in family planning centres</p> <p><i>Victoria Manda, Julie Castaneda, Jean Guilleminot, Fati Abdou, Samantha Devlin, Eleanor Friedman, Jessica P. Ridgway, Amy K. Johnson, Geoffroy Liegeon (Paris, France)</i></p>
P024	<p>Determinants of loss to follow-up among pre-exposure prophylaxis users at a Portuguese tertiary hospital</p> <p><i>Sara Magalhães, Sara Lino, Raquel Pinto, Maria Carlos, Gonçalo Cristóvão, Ana Catarina Gonçalves, João Caria, Vasco Almeida, Claudina Cruz, Marta Leal Santos, Diogo Bento, Stepanka Betkova, Raquel Garrote, Freddy Ramirez, Diana Póvoas, Diana Seixas, Orlando Cardoso, Maria José Manata, Fernando Maltez (Lisboa, Portugal)</i></p>
P025	<p>Evolution from an HIV PrEP clinic to a comprehensive sexual health service in a tertiary university hospital in southeast Asia</p> <p><i>Dariusz Olszyna, Tiane Le, Sophia Archuleta (Singapore, Singapore)</i></p>
P026 Virtual	<p>HIV incident infections in a PrEP cohort</p> <p><i>Isabel Pastor, Guillermo Alberto Vilorio, Mariana Angelica Kundro, Marina Alonso Serena, Maria Belen Zorz, Federico Cardozo, Marcelo Horacio Losso (Buenos Aires, Argentina)</i></p>
P027	<p>Prevalence of the use of sports supplements and illicit drugs for use in gyms in people included in HIV pre-exposure prophylaxis programmes (Gym-PrEP cohort)</p> <p><i>Raquel Muñoz-Andrés, Sara de la Fuente Moral, Natalia Vicente-López, Ilduara Pintos-Ramos, Alberto Díaz de Santiago (Madrid, Spain)</i></p>
P028 Virtual	<p>Injectable PrEP is here, who wants it? Early lessons learned from injectable cabotegravir rollout in Zambia</p> <p><i>Daniel Mwamba (Lusaka, Zambia)</i></p>
P029	<p>PrEP-associated stigma in Europe: findings from a real-world survey</p> <p><i>Melanie Schroeder, Fritha Hennessy, Libby Turner, Tim Holbrook, Ama Appiah, Jenny Scherzer (Munich, Germany)</i></p>
P030	<p>Implementation of PrEP in Italy: results of PrIDE survey</p> <p><i>Silvia Nozza, Valentina Mazzotta, Thomas Masoero, Alessandro Tavelli, Filippo Leserri, Lucia Taramasso, Daniele Tesoro, Enrico Tesoro, Antonella D'Arminio Monforte, Francesco Maria Fusco, Marianna Menozzi, Eugenio Milano, Davide Moschese, Roberto Rossotti, Francesco Barbaro, Salvio Cecere, Maddalena Giglia, Serena Venturelli, Massimo Cernuschi, Antonella Castagna, Andrea Antinori (Milano, Italy)</i></p>

Scientific Posters

ARV-based Prevention – PrEP (continued)

P031	<p>Dynamics of STIs during and after the COVID-19 pandemic in PrEP-cohort at the University Medical Center Hamburg-Eppendorf (UKE) <i>Nils Janis Steinhaus, Maher Almahfoud, Lukas Weimann, Hanna Matthews, Philine Diekhoff, Selina Pollich, Sabine Jordan, Till Koch, Guido Schaefer, Anja-Dorothee Huefner, Stefan Schmiedel, Julian Schulze zur Wiesch, Olaf Degen (Hamburg, Germany)</i></p>
P032	<p>Does tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis induce changes in kidney function in people older than 50 years old? <i>Francisco Novela, Flávia Faria, Ema Pos, Soraia Almeida, Ana Cipriano, Josefina Mendez (Porto, Portugal)</i></p>
P033 Virtual	<p>There are still myths and misconceptions about it!! Assessing pre-exposure prophylaxis knowledge among adolescents in Zambia, a mixed method survey <i>Yvonne Kumwimba (Lusaka, Zambia)</i></p>
P034	<p>Clinical landscape of sexually transmitted infections among PrEP users: insights from a district hospital <i>Clara Bacelar, Fábio Reis, Eduarda Pena, Sara Araújo, Clara Batista, Ricardo Correia de Abreu, Frederico Duarte (Matosinhos, Portugal)</i></p>

Treatment Strategies – Novel therapeutic targets (phase I and II)

P035	<p>Pharmacokinetic/pharmacodynamic and resistance analyses of GS-1720, a once-weekly oral integrase strand transfer inhibitor <i>Brie Falkard, Haeyoung Zhang, Mutaz Jaber, Eva Mortensen, Furong Wang, Christian Callebaut, Dhananjay D. Marathe (Foster City, CA, USA)</i></p>
P036	<p>Effect of acid-reducing agents on the pharmacokinetics of oral GS-4182 <i>Naveed Shaik, Sean Regan, Deqing Xiao, Furong Wang, Jason Hindman, Ramesh Palaparthi (Foster City, CA, USA)</i></p>
P037	<p>Correlation of baseline phenotypic sensitivity with virological response to VH3810109 (N6LS) in BANNER <i>Margaret Gartland, Peter Leone, Judah Abberbock, Kathryn Brown, Paul Wannamaker, Rulan Griesel, Viviana Wilches, Jan Losos (Durham, NC, USA)</i></p>
P038	<p>Polyphenol-rich Camu Camu capsules effect on weight and liver markers in people living with HIV on antiretroviral therapy: results of the Camu Camu pilot study (CTN PT 032) <i>Stephane Isnard, Léna Royston, Tsoarello Mabanga, Carolina A. Berini, Amélie Pagliuzza, Talat Bessissow, Peter L. Lakatos, Thibault Varin, Emendez Salazar, Taiki Hakozaki, Bertrand Lebouché, Cecilia T. Costiniuk, Giada Sebastiani, Marina Klein, Nicolas Chomont, Bertrand Routy, André Marette, Jean-Pierre Routy (Montreal, Canada)</i></p>
P039	<p>Geno2pheno-bNAbs: interpretable and accurate prediction of HIV-1 bNAbs resistance <i>Martin Pirkel, Michael Boehm, Joachim Buech, Philipp Schommers, Florian Klein, Rolf Kaiser, Thomas Lengauer (Cologne, Germany)</i></p>

Treatment Strategies – RCTs: oral and injectable therapy in first line and suppressed switch populations

P040	<p>Similar virological outcomes and frequency of isolated viraemic events (blips, low-level viraemia and suspected virological failure) between oral and long-acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir + rilpivirine long-acting studies <i>John Thornhill, Louise Garside, Chinyere Okoli, Patricia de los Rios, Kimberley Brown, Lori A. Gordon, Christine L. Latham, William Spreen (Brentford, UK)</i></p>
------	---

Scientific Posters

Treatment Strategies – RCTs: oral and injectable therapy in first line and suppressed switch populations (continued)

P041	<p>Doravirine plus raltegravir (DOR/RAL) two-drug regimen (2-DR) as a maintenance antiretroviral therapy in virally suppressed people living with HIV (PLWH): results of the international randomized DORAL trial <i>Romain Palich, Antonella Castagna, Clotilde Allavena, Andrea Antinori, Diana Canetti, Juan Tiraboschi, Claudine Duvivier, Esteban Martinez, Pere Domingo, Salima Barkat, Yasmine Dudoit, Lydie Beniguel, Gilles Peytavin, Cathia Soulié, Anne-Geneviève Marcelin, Lambert Assoumou, Christine Katlama (Paris, France)</i></p>
P042	<p>Viral blips in the doravirine phase III clinical trials DRIVE-FORWARD and DRIVE-AHEAD <i>Jean-Michel Molina, Chloe Orkin, Roger Paredes, Zhi Jin Xu, Feng-Hsiu Su, Ernest Asante-Appiah, Rebeca M. Plank, Rima Lahoulou (Paris, France)</i></p>
P043	<p>Long-term efficacy and safety of dolutegravir/lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial - GESIDA 11820 <i>Maria de Laqarde Sebastian, Rosa de Miguel Buckley, Jose Luis Blanco-Arevalo, Adriana Pinto, Rocio Montejano Sanchez, Angela Gutiérrez Liarte, Roser Navarro-Soler, Esperanza Cañas Ruano, Alexy Inciarte, Luz Martin-Carbonero, Arkaitz Imaz, Cristina Hernandez Gutierrez, Antonio Ocampo Hermida, Marta de Miguel, Rafael Delgado Vazquez, Federico Pulido Ortega, Jose Ramon Arribas Lopez (Madrid, Spain)</i></p>
P044	<p>Efficacy of dolutegravir plus lamivudine in treatment-naïve people living with HIV without baseline drug-resistance testing available: 48-week results from the randomised D2ARLING study <i>Ezequiel Cordova, Jeniffer Hernandez Rendon, Veronica Mingrone, Patricio Martin, Gisela Arevalo Calderon, Soledad Seleme, Jamile Ballivian, Norma Porteiro (Buenos Aires, Argentina)</i></p>
P045 Virtual	<p>Virological suppression, viral blip, low-level viraemia, and confirmed viraemia in virologically suppressed people with HIV-1 switching to tenofovir DF-containing, ainoovirine-based antiretroviral regimen: secondary, and subgroup virological efficacy analyses of the SPRINT trial, a randomized, active-controlled phase III study <i>Fujie Zhang, Hao Wu, Weiping Cai, Ping Ma, Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Wan Wan, Heliang Fu, Hong Qin (Yangzhou, China)</i></p>
P046 Virtual	<p>High virological suppression in treatment-naïve people with HIV-1 on ainoovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-centre, randomized, active-controlled study <i>Fujie Zhang, Qun Li, Fengting Yu, Hao Wu, Weiping Cai, Qingxia Zhao, Min Wang, Yaokai Chen, Hongxia Wei, Hong Qin (Yangzhou, China)</i></p>
P047	<p>An EYEWITNESS to successful diversity in antiretroviral switch studies <i>Cornelius Van Dam, Maria Jose Crusells-Canales, Bliss Leverette, Mounir Ait-Khaled, Emilio Letang, Alex Pitchford, Richard Grove, Riya Moodley, Karen Anderson, Deanna Merrill, Miguel Pascual-Bernaldez, V. Paul DiMondi, Bryn Jones (Durham, NC, USA)</i></p>
P048	<p>Changes in patient-reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO-DOBLE randomized clinical trial <i>Lucio Garcia-Fraile, Mar Masia, Maria J. Crusells-Canales, Pere Domingo, Adria Curran, Roberto Guerri-Fernandez, Enrique Bernal, Joaquin Bravo, Boris Revollo, Juan Macias, Juan M. Tiraboschi, Rocio Montejano Sanchez, Concepcion Amador, Miguel Torralba, Dolores Merino, Vicens Diaz-Brito, Maria J. Galindo Puerto, Sergio Ferra, Aroa Villoslada, Juan E. Losa, Francisco J. Fanjul, Javier Perez-Stachowski, Joaquim Peraire, Joaquin Portilla, Sara de la Fuente Moral, Carlos Dueñas, Maria J. Vazquez, Silvana Di Gregorio, Eduardo Manzanares, Pedro Gil, Marta de Miguel, Jose Luis Blanco-Arevalo, Pablo Ryan, Belen Alejos, Esteban Martinez (Barcelona, Spain)</i></p>

Scientific Posters

Treatment Strategies – RCTs: oral and injectable therapy in first line and suppressed switch populations (continued)

P049	<p>Pharmacokinetic (PK) analysis of oral once-daily bicitgravir (BIC) plus lenacapavir (LEN) administered separately (BIC 75 mg + LEN 25 mg; BIC 75 mg + LEN 50 mg) and as BIC/LEN 75/50 mg single-tablet regimen to support phase III dose selection</p> <p><i>Priyanka Arora, Elise Oh, Jairo M. Montezuma-Rusca, Peter Sklar, Deqing Xiao, Nieves Velez de Mendizabal, Ramesh Palaparthi, Dhananjay D. Marathe (Foster City, CA, USA)</i></p>
P050	<p>Metabolic changes at 48 weeks in virologically suppressed people with HIV switching from complex antiretroviral regimens to bicitgravir plus lenacapavir: ARTISTRY-1 trial</p> <p><i>David Prelutsky, Karam Mounzer, Moti Ramgopal, Jihad Slim, Malcolm Hedgcock, Sorana Segal-Maurer, Mark Bloch, Xu Zhang, Jairo M. Montezuma-Rusca, Peter Sklar, Peter Ruane (Foster City, CA, USA)</i></p>
P051	<p>Comparison of treatment-emergent resistance associated mutations among single tablet regimens and cabotegravir+rilpivirine for the treatment of virologically suppressed people with HIV: a systematic literature review and network meta-analysis</p> <p><i>Ishfaq Rashid, Teerapon Dhippayom, Connor Willis, Howard Weston Schmutz, Moti Ramgopal, Elizabeth Sherman, Rachel Safran, Nicholas Yared, Amy R. Weinberg, Soodi Navadeh, Nathan R. Unger, Nathorn Chaiyakunapruk (Fort Pierce, FL, USA)</i></p>
P052 Virtual	<p>Virological outcomes and resistance profile in people with HIV-1 switching to ainoovirine- from NNRTI-based antiretroviral regimen containing two-NRTI backbone: the integrated efficacy analysis of the RACER-EXT and SPRINT studies, two multi-centre, randomized, active-controlled phase III trials</p> <p><i>Yaokai Chen, Min Wang, Fujie Zhang, Hao Wu, Weiping Cai, Ping Ma, Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Wan Wan, Heliang Fu, Hong Qin (Yangzhou, China)</i></p>
P053 Virtual	<p>Predictive efficacy of dual therapy combining integrase strand transfer inhibitors with second-generation non-nucleoside reverse transcriptase inhibitors following HIV-1 treatment failure in Cameroon: potential implications for the use of long-acting therapeutic strategy in low- and middle-income countries</p> <p><i>Davy Hyacinthe Gouissi Anquechia, Yagai Boubou, Ezechiel Ngoufack Jagni Semengue, Desire Takou, Aude Ka'e, Collins Chenwi Ambe, Grace Beloumou, Alexis Ndjolo, Nicaise Ndembi, Vittorio Colizzi, Carlo-Federico Perno, Joseph Fokam (Yaounde, Cameroon)</i></p>
P054	<p>RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF</p> <p><i>Sophie Degroote, Evy Blomme, Liesbeth Delesie, Linos Vandekerckhove, Marie-Angélique De Scheerder (Ghent, Belgium)</i></p>
P055 Virtual	<p>Immunological efficacy and early response in virologically suppressed people with HIV-1 switching to tenofovir DF-containing, ainoovirine-based compared to tenofovir alafenamide-containing, boosted elvitegravir-based antiretroviral regimen: secondary immunological efficacy analyses of the SPRINT trial, a randomized, active-controlled phase III study</p> <p><i>Hao Wu, Weiping Cai, Ping Ma, Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Fujie Zhang, Wan Wan, Heliang Fu, Hong Qin (Yangzhou, China)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy

P056	<p>Real world outcomes of cabotegravir and rilpivirine for treating PLHIV in Spain: a multicentre, ambispective and nationwide study (the RELATIVITY cohort)</p> <p><i>Luis Buzon Martin, Montes Maria Luisa, Maria J. Galindo Puerto, Miguel Torralba González, Guillermo Pousada, Mireia Santacreu, Ignacio de los Santos, Alfonso Cabello Úbeda, Noemi Cabello Clotet, María José Crusells-Canales, Luis Enrique Morano, Patricia Martin Rico, Carmen Montero Hernández, Alberto Diaz de Santiago, Álvaro Cecilio, Miguel Zárraga Fernández, Enrique Bernal, María Antonia Sepúlveda, María Jesús Vivancos Gallego, Roberto Pedrero Tomé, Mar Masiá Canuto, Ruth Calderón Hernáiz, Cristina Diez Romero, Juan Emilio Losa García, Manuel Gutiérrez Cuadra, Jara Llenas-García, Ana Cerezales Calviño, Antonio Sánchez Guirao, Josefa Soler González, Miriam Estébanez, Beatriz de la Calle Riaguas, María Ángeles Garcinuño Jiménez, Maria del M. García Navarro, Noemi Ramos Vicente, Marta Clavero Olmos, Miguel Egido Murciano, Eva Ferreira Pasos, Jesús Troya García (Burgos, Spain)</i></p>
P057	<p>Antiretroviral treatment in PLWH with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: a real-world cohort analysis</p> <p><i>Gundolf Schuettfort, Alfonso Cabello, Maria Crusells-Canales, Miguel Gorgolas Hernández-Mora, Carmen Hidalgo-Tenorio, Juan Lopez, Rafael Mican, Roser Navarro-Soler, Eugenia Negredo, Sebastian Noe, Jordi Puig, Jürgen Rockstroh, Sergio Rodriguez, Rosario Serrao, Christoph Stephan, Miguel Torralba, Diva Trigo, Maria Vivancos, Annette Haberl (Frankfurt, Germany)</i></p>
P058	<p>Long acting cabotegravir plus lenacapavir as a fully injectable maintenance antiretroviral regimen in people with HIV with adherence issues</p> <p><i>Romain Palich, Romain Manchon, Jérémy Zeggagh, Elisabete Gomes-Pires, Sophie Seang, Marc-Antoine Valantin, Marc Wirden, Marianne Burgard, Gilles Peytavin, Claudine Duvivier (Paris, France)</i></p>
P059	<p>Real world experience of DTG+3TC regimen: results from the French Dat'AIDS cohort (2015-2022)</p> <p><i>Clotilde Allavena, Romain Palich, Alain Makinson, Amélie Ménard, David Rey, Laetitia Roustand, Corinne Vouillot, Laurent Hocqueloux (Nantes, France)</i></p>
P060	<p>Feasibility, acceptability and effectiveness of long acting injectable antiretrovirals in the "Acceptability and Feasibility of long-acting INjectable ART in Adolescents and Young Adults (AFINAty)" study in South Africa</p> <p><i>Lauren Jennings, Millicent Atujuna, Chantel Schreuder, Nyiko Mashele, Metsekae Madimabe, Linda-Gail Bekker, Catherine Orrell (Cape Town, South Africa)</i></p>
P061	<p>Durability of doravirine containing regimens in people with HIV in real-life settings in the ANRS CO3 cohort: AQUIVIH-NA</p> <p><i>Olivier Leleux, Alaric Peyrouny-Mazeau, Adélaïde Perrier, Mojgan Hessamfar, Gwenaël Le Moal, Didier Neau, Laure Alleman, Charles Cazanave, Estibaliz Lazaro, Pierre Duffau, Agnès Riché, Yann Gérard, Marie-Anne Vandenhende, Fabrice Bonnet (Bordeaux, France)</i></p>
P062	<p>Re-suppression regimens and outcomes after virological failure in randomized controlled trials and real-world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV)</p> <p><i>Alexa Elias, Melanie Smuk, Kyle Ring, Chloe Orkin (London, UK)</i></p>
P063	<p>Four-year outcomes from the BICSTaR study: observational analysis of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV in Canada, France, and Germany</p> <p><i>Alex Wong, Daniel Beer, Claudine Duvivier, Hugues Cordel, Anja Meurer, David Thorpe, Marion Heinzkill, Andrea Marongiu, Johanna Ramroth, Benoit Trottier (Saskatchewan, Canada)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

<p>P064</p>	<p>Long-acting injectable cabotegravir and rilpivirine outcomes in HIV-positive migrants in Spain: do they have worse outcomes? <i>Jara Llenas-García, Roberto Pedrero Tome, Luis Ramos Ruperto, María José Galindo Puerto, Mariano Matarranz del Amo, Carolina Navarro, Miguel Torralba, Gutiérrez Lara, María Aguilera García, Alfonso Cabello Úbeda, Isabel San Joaquín Conde, Luis Enrique Morano, Noemí Cabello-Clotet, Patricia Martín Rico, Carmen Montero Hernández, Elisa Pino, Alberto Díaz de Santiago, Ruth Calderón Hernaiz, Enrique Bernal, María Jesús Vivancos Gallego, María Antonia Sepúlveda, Chiara Fanciulli, Álvaro Cecilio, Josefa Soler González, Sergio Padilla, Juan Emilio Losa García, Carlos Armiñanzas Castillo, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, María Ángeles Garcinuño Jiménez, Eva Ferreira Pasos, Miriam Estébanez, Beatriz de la Calle Riaguas, Teresa Omiste Sanvicente, Noemí Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, Ana Lucas Dato, on behalf of the Relativity Multicentre Cohort (Orihuela, Spain)</i></p>
<p>P065 Virtual</p>	<p>Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine in women: a substudy of the RELATIVITY cohort <i>Maria Jose Galindo Puerto, Noemí Cabello Clotet, Teresa Aldamiz-Echevarría Lois, Jara Llenas García, Mari Mar Arcos, Jesús Troya, Luis Buzón Martín, Miguel Torralba, Mireia Santacreu, Maria Aguilera García, Alfonso Cabello Úbeda, Maria Jose Crusells-Canales, Luis Morano, Roberto Pedrero Tomé, Patricia Martin Rico, Carmen Montero Hernández, Desiree Perez Martinez, Sara de la Fuente Moral, Ruth Calderón Hernaiz, Enrique Bernal, María Jesus Vivancos Gallego, Maria Antonia Sepúlveda, Alvaro Cecilio, Víctor Arenas García, Sergio Padilla, Juan Emilio Losa García, Francisco Arnaiz de las Revillas Almajano, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, Maria Angeles Garcinuño Jiménez, Eva Maria Ferreira Pasos, Miriam Estebanez, Beatriz De la Calle Riaguas, Miguel Egido Murciano, Noemí Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, on behalf of the RELATIVITY Multicentre Cohort (Valencia, Spain)</i></p>
<p>P066</p>	<p>Causes of discontinuation of long-acting cabotegravir and rilpivirine in clinical practice: results from the prospective multicentre SCOLTA cohort <i>Lucia Taramasso, Nicola Squillace, Elena Ricci, Sergio Ferrara, Giancarlo Orofino, Eleonora Sarchi, Emanuele Pontali, Giovanni Cenderello, Giovanni Francesco Pellicanò, Filippo Lagi, Elena Salomoni, Olivia Bargiacchi, Maria Aurora Carleo, Luigi Pusterla, Salvatore Martini, Rita Bellagamba, Giordano Madeddu, Giuseppe Vittorio De Socio, Barbara Menzaghi, Goffredo Angioni, Katia Falasca, Antonio Cascio, Antonio Di Biagio, Paolo Bonfanti (Monza, Italy)</i></p>
<p>P067</p>	<p>Treatment patterns in virologically suppressed, treatment-experienced people with HIV: a US real-world database study <i>Samir Gupta, Katherine Cappell, Kwanza Price, Machaon Bonafede, Joshua Gruber, JeanPierre Coaquira Castro, Soodi Navadeh, Robert Sedgley, Sorana Segal-Maurer (Foster City, CA, USA)</i></p>
<p>P068</p>	<p>Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence <i>Marta Boffito, Jason Brunetta, Itzchak Levy, Chia-Jui Yang, Joaquín Portilla, Eoghan De Barra, Roger Vogelmann, Tomoyuki Endo, Olivier Robineau, Loredana Sarmati, David Thorpe, Andrea Marongiu, Tali Cassidy, Berend van Welzen (London, UK)</i></p>
<p>P069</p>	<p>Long-acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients <i>Ana Moreno, Santos Del Campo, Maria Jesus Perez-Elias, Jose Luis Casado, Miguel Garcia, Manuel Velez, Maria Jesus Vivancos, Santiago Moreno (Madrid, Spain)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

P070 Virtual	<p>Early virological and immunological effectiveness of ainoovirine- compared to efavirenz-based antiretroviral regimen as initial therapy in treatment-naive people with HIV-1: the pooled analysis of prospective or retrospective real-world studies</p> <p><i>Hai Long, Linghua Li, Min Wang, Shangjie Wu, Quan Zhang, Zhong Chen, Quanying He, Shujing Ma, Lei Guo, Yufang Zheng, Chunyun Zhang, <u>Hong Qin</u> (Yangzhou, China)</i></p>
P071	<p>Switching from integrase strand transfer inhibitors (INSTIs) based triple therapy to dual therapy in people with HIV-1 infection (PWH): the French hospital database on HIV (ANRS CO4 FHDH) real-life experience</p> <p><i>Emilie Lanoy, Claudine Duvivier, Nathalie De Castro, Sophie Abgrall, Sylvie Bregigeon-Ronot, Fabienne Caby, Colin Deschanvres, Jade Ghosn, Marina Karmochkine, Christine Katlama, Odile Launay, Christian Pradier, Jacques Reynes, Dominique Salmon, Dominique Costagliola, <u>Sophie Grabar</u> (Paris, France)</i></p>
P072	<p>Central nervous system safety of long-acting cabotegravir/rilpivirine in patients with previous oral INSTI-related CNS toxicity</p> <p><i><u>Ana Moreno</u>, Santos Del Campo, Maria Jesus Vivancos, Manuel Velez, Jose Luis Casado, Javier Martinez, Fernando Dronza, Santiago Moreno, Maria Jesus Perez-Elias (Madrid, Spain)</i></p>
P073	<p>DTG/3TC as initial therapy in people living with HIV and viral load >500,000 copies/mL</p> <p><i>Juan Martin, <u>Maria Lagarde</u>, Judit Iglesias, David Rial, Otilia Bisbal-Pardo, Adriana Pinto, Roser Navarro, Mireia Santacreu, Maria Teresa Lopez, Laura Bermejo, Maria Asuncion Hernando, Rafael Rubio, Federico Pulido Ortega (Madrid, Spain)</i></p>
P074	<p>Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort</p> <p><i><u>Giada Canavesi</u>, Maurizio Mena, Elena Zaninetta, Lidia Gazzola, Teresa Bini, Giancarlo Orofino, Andrea De Vito, Giordano Madeddu, Chiara Grillo, Claudia Bartalucci, Federica Centorrino, Nicola Squillace, Paolo Bonfanti, Giorgio Tiecco, Emanuele Focà, Marianna Menozzi, Giovanni Guaraldi, Nicolas Brian Bana, Giovanni Cavazza, Roberto Rossotti, Sergio Lo Caputo, Antonio Di Biagio, Stefano Rusconi (Legnano, Italy)</i></p>
P075	<p>Real-life effectiveness, safety and acceptance of long-acting cabotegravir-rilpivirine: results from a large single-centre cohort</p> <p><i><u>Ana González-Cordón</u>, Montse Laguno, Leire Berrocal, Maria Martínez-Rebollar, Berta Torres, Ivan Chivite, Alexy Inciarte, Paula Arreba, Juan Ambrosioni, Alberto Foncillas, Lorena de la Mora, José Luis Blanco-Arevalo, Júlia Calvo, Esteban Martinez, Abiu Sempere, Jose M. Miro, Roger Llobet, Elisa de Lazzari, Josep Mallolas (Barcelona, Spain)</i></p>
P076	<p>Persistence, safety and virological outcomes of B/F/TAF as a baseline or switch regimen in HIV-infected people living with advanced HIV disease in the real world: the BIC-CD4 study</p> <p><i><u>Diego Cecchini</u>, Carla Serrano, Martín Brizuela, María Magdalena Puchulu, Gastón Copertari, Brenda Bacelar, Juan Manuel Nuñez, Juan Gonzalo Tomás, Romina Mauas, Macarena Roel, Edgardo Bottaro, Isabel Cassetti (Buenos Aires, Argentina)</i></p>
P077	<p>Effectiveness of long-acting ART with cabotegravir/rilpivirine in the Icona Cohort</p> <p><i>Roberta Gagliardini, Sara De Benedittis, <u>Alessandro Tavelli</u>, Giuseppe Lapadula, Valentina Mazzotta, Elena Bruzzesi, Adriana Cervo, Giorgia Carrozzo, Annalisa Sarracino, Stefano Rusconi, Giulia Marchetti, Francesca Ceccherini-Silberstein, Andrea Antinori, Antonella d'Arminio Monforte, Camilla Muccini (Milan, Italy)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

P078	<p>Use of long-acting cabotegravir and rilpivirine in a real-life setting: 12-month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiviH-NA Cohort-France <i>Mojgan Hessamfar, Olivier Leleux, Alaric Peyrouny-Mazeau, Camille Krzyzanowsky, Gwenaël Le Moal, Didier Neau, Hélène Ferrand, Arnaud Desclaux, Estibaliz Lazaro, Pierre Duffau, Yann Gérard, Marie-Anne Vandenhende, Fabrice Bonnet (Bordeaux, France)</i></p>
P079	<p>Switching to LA CAB/RPV in virologically suppressed PLHIV: does knowing previous genotyping really matter? A substudy from the RELATIVITY cohort <i>Luis Buzon Martin, María Luisa Montes, María José Galindo Puerto, Miguel Torralba, Victoria Mancheño De Real, María Aguilera García, Alfonso Cabello Úbeda, Isabel San Joaquín Conde, Luis Morano, Noemi Cabello Clotet, Patricia Martín Rico, Carmen Montero Hernández, Miguel de Zárraga Fernández, Sara de la Fuente Moral, Ruth Calderón Hernaiz, Enrique Bernal, María Jesús Vivancos Gallego, María Antonia Sepúlveda, Roberto Pedrero Tomé, Cristina Diez Romero, Álvaro Cecilio, Jara Llenas-García, Victor Arenas García, Mar Masiá Canuto, Juan Emilio Losa García, Carlos Armiñanzas Castillo, Antonio Jesús Sánchez Guirao, María del Mar García Navarro, Ana Cerezales Calviño, María Ángeles Garcinuño Jiménez, Eva Ferreira Pasos, Miriam Estébanez, Beatriz de la Calle Riaguas, Miguel Egido Murciano, Noemi Ramos Vicente, Marta Clavero Olmos, Juan Manuel Tiraboschi, Jesús Troya (Burgos, Spain)</i></p>
P080	<p>To describe the prevalence of virological failure and resistance patterns to long-acting cabotegravir-rilpivirine: a real-life single-centre cohort study <i>Ana González-Cordón, Alexy Inciarte, Mar Mosquera, Leire Berrocal, Maria Martinez-Rebollar, Berta Torres, Ivan Chivite, Paula Arriba, Juan Ambrosioni, Alberto Foncillas, Lorena De La Mora, Julia Calvo, Abiu Sempere, Jose M. Miro, Roger Llobet, Elisa De Lazzari, Josep Mallolas, Esteban Martinez, Montserrat Laguno, Jose Luis Blanco-Arevalo (Barcelona, Spain)</i></p>
P081	<p>Long-acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real-world study (RELATIVITY Cohort) <i>Jesús Troya, Luis Morano, Jose Ignacio Bernardino, Luis Buzón Martin, Roberto Pedrero Tomé, María José Galindo Puerto, Miguel Torralba, Noemí Cabello Clotet, María García López, Silvia Lope, Miguel Alberto de Zárraga Fernández, Alfonso Cabello, María Aguilera García, Álvaro Cecilio, Alberto Díaz de Santiago, María Ángeles Garcinuño Jiménez, Enrique Bernal, María Teresa López Caballero, Ruth Calderón Hernaiz, María Jesús Vivancos Gallego, Teresa Omiste Sanvicente, Eva Ferreira Pasos, Juan Emilio Losa García, Josefa Francisca Soler González, María Antonia Sepulveda, María del Mar García Navarro, on behalf of the RELATIVITY Multicentre Cohort (Madrid, Spain)</i></p>
P082 Virtual	<p>CARAVEL: evaluation of real-world effectiveness and sustainability of the two-drug regimen dolutegravir/lamivudine fixed-dose combination in treatment-naive adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France: 2-year interim analysis results <i>Patrick Philibert, Charlotte Charpentier, Nilakshani Naguleswaran, Caroline Philippe, Laetitia Roustand, Corinne Vouillot, Laurent Hocqueloux (Marseille, France)</i></p>
P083	<p>Incidence of comorbidities over 18 months with BIC/FTC/TAF, DTG/ABC/3TC or DTG/3TC in real-life settings in the ANRS-CO3-AquiviH-NA cohort <i>Olivier Leleux, Alaric Peyrouny-Mazeau, Adélaïde Perrier, Mojgan Hessamfar, Gwenaël Le Moal, Didier Neau, Laure Alleman, Charles Cazanave, Estibaliz Lazaro, Pierre Duffau, Agnès Riché, Yann Gérard, Marie-Anne Vandenhende, Fabrice Bonnet (Bordeaux, France)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

P084	Real-world utilization of cabotegravir + rilpivirine in Southern Spain: data from the CARIPLA study <i>Rosario Palacios, Cristina Gómez-Ayerbe, Marisa Mayorga, Nuria Espinosa, Alicia Hidalgo, Francisco Téllez, Ana Belén Lozano, Mónica Loring, Jesús Santos (Málaga, Spain)</i>
P085	HIV-2 chronic infection and BIC/FTC/TAF experience in a Portuguese tertiary hospital in Lisbon <i>Marqarida Almeida, Constança Antunes, Mariana Pereira, Marta Almeida, Ana Cláudia Miranda, Kamal Mansinho (Lisboa, Portugal)</i>
P086	Discontinuation of rilpivirine and cabotegravir in HIV-1 virologically suppressed adults: a multicentre observational study in Tuscany (LAHIV study) <i>Filippo Laqi, Giuseppe Formica, Massimiliano Fabbiani, Barbara Rossetti, Matteo Piccica, Susanna Giachè, Daniela Messeri, Silvia Costarelli, Erika Riguccini, Giovanni Sarteschi, Michele De Gennaro, Emanuela Francalanci, Giuseppe Gasparro, Marco Fognani, Riccardo Paggi, Paola Corsi, Marco Pozzi, Gaetana Sterrantino, Mario Tumbarello, Pierluigi Blanc, Filippo Bartalesi, Donatella Aquilini, Cesira Nencioni, Danilo Tacconi, Spartaco Sani, Antonella Vincenti, Alessandro Bartoloni (Florence, Italy)</i>
P087 Virtual	Effectiveness and safety of BIC/FTC/TAF for late-presenting people with HIV-1 infection <i>Hai Long, Xiaoxin Xie, Xiaoyan Yang, Yanhua Fu, Lin Gan, Shujing Ma (Guiyang, China)</i>
P088	Virological failure rate and emergent resistance in real-world studies evaluating long-acting cabotegravir and rilpivirine in people with baseline viral suppression <i>Melanie Smuk, Alexa Elias, Kyle Ring, Chloe Orkin (London, UK)</i>
P089	Profile of people with HIV (PWH) switching prior antiretroviral treatment (ART) to a doravirine (DOR)-based regimen in the real-world clinical setting in Greece: the DORAVITO study <i>Antonios Papadopoulos, George Adamis, Panagiota Lourida, Vassileios Paparizos, Helen Sambatakou, Symeon Metallidis, Charalampos Moschopoulos, Myrto Astriti, Charisis Totsikas, Varvara Vasalou, Eleni Boutselakou, Dimitris Tsokos, Georgios Trimis, Lazaros Poughias (Athens, Greece)</i>
P090	PLWH treated with cabotegravir-rilpivirine have increased CD4/CD8 ratio and decreased CD8 T-cells, as expression of lower inflammation, while maintaining virological suppression: a real-life 48 weeks analysis <i>Giuseppe Nunnari, Serena Spampinato, Giuseppe Nicolo Conti, Carmen Giarratana, Teresa Cirelli, Viviana Coco, Michele Salvatore Paterno Raddusa, Viviana Fisicaro, Chiara Gullotta, Roberto Bruno, Eugenia Pistarà, Nunziatina Villari, Bruno Cacopardo, Emmanuele Venanzi Rullo, Andrea Marino, Benedetto Maurizio Celasia, Giovanni Pellicanò, Alessia Mirabile (Catania, Italy)</i>
P091	Discontinuation rates of doravirine/lamivudine/tenofovir-DF due to neuropsychiatric adverse effects <i>Iresh Jayaweera, Rory Grier-Gavin, Rosy Weston, Nicola Mackie, Lucy Garvey, John Walsh, Alan Winston, Borja Mora-Peris (London, UK)</i>
P092	Switch to dolutegravir/lamivudine in virologically suppressed people living with HIV: a real-world experience in a low-middle income country <i>Julian Vega, Micaela Sogga Alfano, María Clara Villaverde, Alejandra Mariaca, Diego Sanchez Thomas, José Ángel Enrique Barletta, María José Rolón, Gustavo Lopardo (Buenos Aires, Argentina)</i>
P093	Effectiveness and safety of dual therapy with co-packed DTG and 3TC compared to triple therapy in clinical practice in Argentina <i>Edgardo Bottaro, Diego Cecchini, Brenda Bacelar, Angeles Tisné, Claudia Migazzi, Macarena Roel, Maximiliano Bergman, Isabel Casseti (Buenos Aires, Argentina)</i>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

<p>P094</p>	<p>Two-year long-term data on the efficacy and tolerability of dolutegravir-based regimens from the prospective multi-centre TESLA cohort study in ART-naïve and pre-treated people living with HIV in Russia <i>Anna Basova, Stella Minaeva, Natalia Sizova, Firaya Nagimova, Elena Orlova-Morozova, Margarita Radzikhovskaya, Valeriy Shevchenko, Andrés Maldonado-Doblado, Bryn Jones (Moscow, Russian Federation)</i></p>
<p>P095</p>	<p>Demographic and clinical characteristics of treatment naïve people with HIV, and their healthcare professionals' reasons for treatment choice: findings from a real-world survey in five European countries <i>Andrea Marongiu, Tali Cassidy, Joshua Gruber, Hannah Jones, Katherine Li, Will Ambler, Fritha Hennessy, Tim Holbrook (Uxbridge, UK)</i></p>
<p>P096</p>	<p>Results at month 7 of CABO-CHANCE study: real-world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH) <i>Carmen Hidalgo-Tenorio, María Aguilera-García, Ignacio De los Santos, David Vinuesa, Mohamed Omar, Ana Lopez Lirola, Enrique Bernal, Onofre Juan Martinez, Alberto Romero, Patricia Sorni, Teresa Lopez, Salvador López Cárdenas, Santiago Moreno, Isabel San Joaquín Conde, José Ramón Blanco, Coral Garcia-Vallecillos (Granada, Spain)</i></p>
<p>P097</p>	<p>Efficacy and safety of long-acting cabotegravir + rilpivirine at All Saints Clinic in Wroclaw (Poland): real-life single-centre 2-year experience <i>Marzena Dawiec, Jacek Gasiorowski, Aleksandra Szymczak, Aleksander Zinzuk, Malgorzata Ingot, Brygida Knysz, Kamila Zielinska, Joanna Bortkiewicz, Michal Furdal, Mateusz Bozejko, Bartosz Szetela (Wroclaw, Poland)</i></p>
<p>P098</p>	<p>Real-world persistence of bictegravir- versus dolutegravir-based single tablet regimens in a large urban Canadian HIV centre <i>David Knox, Jennifer McCully, Graham S. Smith, Negin Mousadifar, Angela Underhill, Taban Saifi, Dylana Mumm, Colin Kovacs, Jason Brunetta, William Tsang, Megan Acsai, Barry Merkley, Kevin Giolma, David Fletcher, Tali Cassidy, Soodi Navadeh, Mona Loutfy (Toronto, Canada)</i></p>
<p>P099</p>	<p>Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long-acting (LA) CAB+RPV administration out of HIV units: the IMADART study <i>Alfonso Cabello, Irene Carrillo Acosta, Aws Al-Hayani, Marta López De Las Heras, Cristina Algar, Inmaculada Burillo, Beatriz Álvarez-Álvarez, Laura Prieto-Pérez, Ignacio Mahillo-Fernández, Macarena Bonilla, Laura García, José Manuel Caraballo, Mónica Esparis, Beatriz Gallego, Javier Bécares, Miguel Górgolas Hernández-Mora (Madrid, Spain)</i></p>
<p>P100</p>	<p>Long-term efficacy, safety and metabolic impact of generic dolutegravir in treatment-naïve and experienced people living with HIV: a real-world study in Argentina <i>Edgardo Bottaro, Angeles Tisne, Brenda Bacelar, Claudia Migazzi, Macarena Roel, Maximiliano Bergman, Diego Cecchini, Isabel Cassetti (Buenos Aires, Argentina)</i></p>
<p>P101</p>	<p>PAIRED - Patient Reported Experiences and perceived benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States <i>Jihad Slim, Andrew P. Brogan, Gavin Harper, Katie Mycock, Abigail McMillan, Deanna Merrill, Gustavo Verdier (Montreal, Canada)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

P102	<p>Factors influencing the prescription of long-acting injectable dual therapy cabotegravir/rilpivirine in a Northwest Paris region cohort</p> <p><i>Jeremie Leporrier, Vincent Daneluzzi, Souhayla Amari, Ghania Bouteira, Séverine Dubois, Feng Zeng, Martine Bloch, Ghislaine Nguisseu, Elisabeth Aslangul (Colombes, France)</i></p>
P103	<p>T-cell homeostasis parameters following switch to injectable cabotegravir plus rilpivirine in virally suppressed people living with HIV (PLWH)</p> <p><i>Camilla Tincati, Leonardo Francesco Rezzonico, Andrea Santoro, Emanuela Ferrante, Teresa Bini, Lidia Gazzola, Giulia Marchetti (Milan, Italy)</i></p>
P104 Virtual	<p>Switching to long-acting intramuscular cabotegravir and rilpivirine in virologically suppressed PLHIV treated with dolutegravir/rilpivirine: a substudy from the RELATIVITY cohort</p> <p><i>María José Galindo Puerto, Luis Buzón Martín, Jesús Troya, Luz Martin Carbonero, Laura Bermejo Plaza, Miguel Torralba, Carmen Montero Hernández, Miguel Alberto de Zárraga Fernández, Roberto Pedrero Tomé, Noemí Cabello Clotet, Víctor Arenas García, Javier García Abellán, Alfonso Cabello Úbeda, Juan Emilio Losa García, María José Crusells-Canales, Jara Llenas García, Beatriz De la Calle Riaguas, Luis Morano, Maria Aguilera García, Patricia Martin Rico, Enrique Bernal, Sara de la Fuente Moral, Ruth Calderón Hernáiz, María Antonia Sepúlveda, Marouane Menchi, Marta Clavero Olmos, Manuel Gutiérrez Cuadra, Miriam Estebanez, Barbara Alonso Moreno, Álvaro Cecilio, Miguel Egidio Murciano, Guillermo Cuevas Tascón, on behalf of the RELATIVITY Multicentre Cohort (Valencia, Spain)</i></p>
P105	<p>Real-world evidence of B/F/TAF in Chile: effectiveness and safety from the BIKUCH cohort</p> <p><i>Alejandro Afani, Alba Rivas, Camila Maulen, Pedro Zitko (Santiago, Chile)</i></p>
P106	<p>Antiretroviral treatment with BIC/FTC/TAF: where we come from and where we are going</p> <p><i>Adrian Rodriguez, Aroa Villoslada, Patricia Sorni, Marta Molero, Antoni Adrover, Ana Andreu, Ana Liebana, Joaquin Serrano, Francisco Homar, Antoni Payeras (Palma, Spain)</i></p>
P107	<p>Patient-reported outcomes in switching to long-acting cabotegravir/rilpivirine: a real-life experience</p> <p><i>Anna Carraro, Raffaella Marocco, Giulia Mancarella, Paola Zuccalà, Lorenzo Ansaldo, Sara De Maria, Sara Corazza, Alessandra Grimaldi, Andrea Gasperin, Cosmo Del Borgo, Miriam Lichtner (Latina, Italy)</i></p>
P108	<p>The analysis of metabolic parameters in people living with HIV using dolutegravir-based regimens in routine clinical practice in Russia</p> <p><i>Anna Basova, Stella Minaeva, Natalia Sizova, Firaya Nagimova, Elena Orlova-Morozova, Margarita Radzikhovskaya, Valeriy Shevchenko, Andrés Maldonado-Doblado, Bryn Jones (Moscow, Russian Federation)</i></p>
P109	<p>Switching from triple therapy to DTG/3TC in HIV-1 infected migrants without previous resistance test results</p> <p><i>Frederico Duarte, Clara Bacelar, Eduarda Pena, Fábio Reis, Clara Batista, Susana Oliveira, Sofia Jordão, Maria João Gonçalves, Sónia Rocha, Cristina Soeiro, Ricardo Correia de Abreu (Matosinhos, Portugal)</i></p>
P110	<p>Real-world experience with 3TC+DTG in low-resource setting in Latin America</p> <p><i>Jimena Lopez Pineiro, Karla Bendezu Mejía, Juan Pablo Stagnaro (La Plata, Argentina)</i></p>
P111	<p>Treatment adherence and virological suppression in an outpatient cohort of people living with HIV (PLWH) on long-acting injectable HIV therapy</p> <p><i>Catharina Dannenberg, Maher Almahfoud, Lukas Weimann, Hanna Matthews, Olaf Degen, Julian Schulze zur Wiesch (Hamburg, Germany)</i></p>

Scientific Posters

Treatment Strategies – Real world and implementation science studies oral and injectable therapy (continued)

P112	<p>Therapy satisfaction and preference for injectable long-term options of Portuguese HIV patients: a multicentric case-study</p> <p><i>Cristina Valente, Ruben Carvalho, Catia Caldas, Carmela Pineiro, Daniel Coutinho, Sofia Nunes, Sara Lino, Fernando Maltez, Raquel Pinho, Josefina Mendez, João Matos, Helder Pinheiro, Inês Vaz Pinto, Frederico Duarte, Ricardo Correia de Abreu, Ricardo Racha-Pacheco (Coimbra, Portugal)</i></p>
P113 Virtual	<p>T-cell homeostasis and microbial translocation in PLWH switching from triple to dual INSTI-based combination antiretroviral therapy (cART)</p> <p><i>Valeria Bono, Camilla Tincati, Matteo Augello, Roberta Rovito, Sabrina Marozin, Andrea Santoro, Giulia Marchetti (Milan, Italy)</i></p>
P114	<p>HIV-1 viral decay in blood and semen in antiretroviral-naive adults initiating dolutegravir/lamivudine versus bicitgravir/emtricitabine/tenofovir alafenamide</p> <p><i>Ran Wang, Yongjian Liu, Lijun Sun, Aixin Li, Shiyun Lv, Yuanyi Zhai, Rui Li, Wei Hua, Xi Wang, Lin Li, lili Dai (Beijing, China)</i></p>

Treatment Strategies – Treatment experienced adults (second-line and multi-drug resistance studies)

P115	<p>Simplification of complex antiretroviral treatment regimens to two-class therapies in people with HIV</p> <p><i>Christine Baumgartner, Dominique Laurent Braun, Huldrych Günthard, Roger Kouyos, Alexandra Calmy, Catia Marzolini, Matthias Cavassini, Enos Bernasconi, Patrick Schmid, Gilles Wandeler, Andri Rauch, Bernard Surial, Anna Hachfeld (Bern, Switzerland)</i></p>
P116	<p>CD4 T-cell, CD4/CD8 ratio improvement and a general reduction in inflammatory biomarkers with low-level viraemia (LLV) up to week 192 with fostemsavir (FTR)-based regimens in individuals with multidrug-resistant (MDR) HIV-1</p> <p><i>Vincenzo Spagnuolo, Natalia Gregori, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Aftan Dyson, Manyu Prakash, Andrew Clark (Brentford, UK)</i></p>
P117	<p>Genotypic assessment of the viability of second-generation NNRTIs as an alternative therapy for ART-experienced individuals with multi-class HIV drug resistance in Botswana</p> <p><i>Nokuthula Ndlovu, Ontlametse Choga, Wonderful Choga, Natasha Moraka, Dorcas Maruapula, Patrick Mokgethi, Kaelo Seatla, David Nkwe, Vlad Novitsky, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)</i></p>
P118	<p>High prevalence of HIV drug resistance among people living with HIV on dolutegravir-based antiretroviral therapy with viral load above 200 copies/mL in Francistown, Botswana</p> <p><i>Ontlametse T. Choga, Goitseone M. Lemogang, Wonderful T. Choga, Gaonyadiwe Muzanywa, Theminkosi M. Shadreck, Charity Ralegoreng, Dorcas Maruapula, Natasha O. Moraka, Catherine K. Koofhethile, Patrick T. Mokgethi, Kedumetse Seru, Boitumelo Zuze, Patience Montshosi, Irene Gobe, Modisa S. Motswaledi, Rosemary Musonda, Tony Chebani, Judith Nawa, Lindani Bochena, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)</i></p>
P119	<p>Replication-competent HIV-1 harbouring resistance-associated mutations is present in the viral reservoir</p> <p><i>Michelle L. D'Antoni, Silvia Chang, Laurie A. VanderVeen, Christian Callebaut (Foster City, CA, USA)</i></p>

Scientific Posters

Treatment Strategies – Treatment experienced adults (second line and multi-drug resistance studies) (continued)

P120	<p>Virological efficacy of dolutegravir plus darunavir in multi-drug-resistant HIV patients: a real-world cohort study with data from the PRESTIGIO Registry <i>Filippo Lagi, Michele Bellomo, Riccardo Lolatto, Filippo Ducci, Seble Tekle Kiros, Rebecka Papaioannu, Tommaso Celemente, Leonardo Calza, Marcello Feasi, Emanuele Focà, Andrea Giacomelli, Roberto Gulminetti, Barbara Menzaghi, Antonella Castagna (Florence, Italy)</i></p>
P121	<p>Effectiveness of switching to B/F/TAF in virologically suppressed people with HIV and with pre-existing resistance-associated mutations in Italy: the BIC-BARRIER Study <i>Federico Conti, Laura Pezzati, Alessandro Cozzi-Lepri, William Gennari, Cristina Mussini, Emanuele Pontali, Anna Volpe, Ilaria Vicenti, Annalisa Saracino, Barbara Rossetti, Bianca Bruzzone, Adrian Shallvari, Laura Albin, Dario Corsini, Maurizio Zazzi, Stefano Rusconi (Lecco, Italy)</i></p>
P122	<p>Switch from etravirine to doravirine as a part of antiretroviral combination in virally suppressed people living with HIV (PLWH): results of the French multicentre, observational SWEED study <i>Romain Palich, Jade Ghosn, Karine Lacombe, Christia Palacios, Pierre Delobel, Pascale Puglièse, Clotilde Allavena, Claudine Duvivier, Firouze Bani-Sadr, Olivier Robineau, Yasmine Dudoit, Duc Hoan, Aissata Kaba, Cathia Soulie, Christine Katlama, Lambert Assoumou (Paris, France)</i></p>
P123	<p>Kinetics of non-nucleosidic reverse transcriptase (NNRT) resistance-associated mutations in HIV-1 blood reservoir in NNRTI-experienced people with HIV: the KINNDer study <i>Thomas Drumel, Justine Sourice, Colin Deschanvres, Audrey Rodallec, Clotilde Allavena, François Raffi, Elisabeth Garnier (Nantes, France)</i></p>
P124	<p>Evidence of resistance to integrase strand transfer inhibitors (INSTIs) among antiretroviral therapy-naïve PLHIV in Greece during 2021-2024 <i>Dimitrios Paraskevis, Evangelia Georgia Kostaki, Eleni Papachristou, Alexandros Vasilakis, Chrysa Rokka, Maria Chini, Georgios Tsekas, Anastasia Antoniadou, Antonios Papadopoulos, Magda Bletsas, Triantafyllia Sotiriadou, Mina Psychogiou, Elpida Mastrogianni, Vasileios Papastamopoulos, Charisis Totsikas, Georgios Adamis, Myrto Astriti, Dimitra Paraskeva, Chrysa Tsiara, Aikaterini Isari, Foteini Giannou, Magdalini Pylli, Nikolaos Sipsas, Olga Kosmopoulou, Georgios Chrysos, Helen Sambatakou, Malvina Lada, Periklis Panagopoulos, Pagona Lagiou, Gkikas Magiorkinis (Athens, Greece)</i></p>
P125	<p>Efficacy and safety of dolutegravir (DTG)-based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): a single-arm clinical trial (DTG-SOT) <i>Jose M. Miro, Daniela Malano Barletta, Leire Berrocal, Christian Manzardo, Anna Castelli, Merce Brunet, Octavi Roman, Juan Ambrosioni, Frederic Cofan, Angela Gonzalez, Pablo Ruiz, Gonzalo Crespo, Alejandro Forner, Maria Angeles Castel, Montserrat Laguno, Montserrat Tuset, Elisa de Lazzari, Antonio Rimola, Asuncion Moreno (Barcelona, Spain)</i></p>
P126	<p>Differentiating APOBEC- and drug-resistant populations by clonal analysis of near full-length proviral HIV-1 genome in highly treatment-experienced people living with HIV <i>Nina Engel, Axelander Thielen, Martin Däumer, Jens Verheyen, Roger Vogelmann (Mannheim, Germany)</i></p>
P127	<p>Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®/BFTAF) in patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) mutations <i>Jane Akodu, Zoe Agyemang, Gavin Marshall, Alan Hunter, Pedro Simoes, Jennifer Hart, Fiona Burns, Tristan J. Barber (London, UK)</i></p>

Scientific Posters

Treatment Strategies – Treatment experienced adults (second line and multi-drug resistance studies) (continued)

P128	<p>Long-term durability of rilpivirine + darunavir/cobicistat dual regimen in antiretroviral-experienced people living with HIV (RilDaco study) <i>Diego Ripamonti, Laura Comi, Federica Borghi, Serena Venturelli, Daniela Valenti, Andrea Francavilla (Bergamo, Italy)</i></p>
P129	<p>Long-term efficacy and safety of a maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate <i>Beatriz Borjabad, Alexis Inciarte, Ivan Chivite, Anna González-Cordon, Maria del Mar Mosquera, Berta Torres, Lorena De La Mora, Maria Martinez-Rebollar, Montserrat Laguno, Alberto Foncillas, Juan Ambrosioni, Josep Mallolas, Cristina Rovira, Carmen Hurtado, Abiu Sempere, Julia Calvo, Leire Berrocal, Josep Maria Miró, Jose Alcamí, Jose Luis Blanco-Arevalo, Sonsoles Sanchez-Palomino, Elisa Lazzari, Esteban Martinez (Sant Joan Despí, Spain)</i></p>
P130 Virtual	<p>Evaluation of HIV-DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under virological control: a longitudinal study from the PRESTIGIO registry <i>Daniele Armenia, Vincenzo Spagnuolo, Maria Concetta Bellocchi, Laura Galli, Greta Marchegiani, Tommaso Clemente, Luca Carioti, Riccardo Lolatto, Micol Ferrara, Roberta Gagliardini, Giulia Carla Marchetti, Carlo Torti, Giuseppe De Socio, Chiara Fornabaio, Maurizio Zazzi, Antonella Castagna, <u>Maria Mercedes Santoro</u> (Rome, Italy)</i></p>
P131	<p>Low prevalence of protease inhibitor mutations among people living with HIV in Botswana: insights from the Botswana Combination Prevention Project <i>Marea Pema, Dorcas Maruapula, Doreen Ditshwanelo, Natasha Moraka, Nokuthula Ndlovu, Ontlametse Bareng, Patrick Mokgethi, Wonderful Choga, Boitumelo Zuze, Catherine Koofhethile, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)</i></p>
P132	<p>Three- versus two-drug doravirine-based regimens: a multicentre observational study <i>Adriana Cervo, Andrea Giacomelli, Roberto Rossotti, Marianna Menozzi, Beatrice Fontana, Elena Martini, Giacomo Menegotto, Maddalena Albertini, Andrea Rabbione, Maria Vittoria Cossu, Davide Moschese, Cristina Gervasoni, Giovanni Guaraldi (Modena, Italy)</i></p>
P133	<p>No impact of the M184I/V mutation on the efficacy of tenofovir or abacavir+lamivudine+doravirine in HIV treatment-experienced people <i>Cathia Soulie, Aliou Baldé, Fofana Djeneba, Charlotte Charpentier, Pascale Bonnafous, Justine Sourice, Anne De Monte, Veronique Avettand-Fenoel, Helene Le Guillou-Guillemette, Laurence Bocket, Stephanie Raymond, Stephanie Marque Juillet, Mary-Anne Trabaud, Brigitte Montes, Anne Maillard, Cedric Hartard, Elodie Alessandri-Gradt, Etienne Brochot, Anne Signori-Schmuck, Lambert Assoumou, <u>Anne-Genevieve Marcelin</u> (Paris, France)</i></p>
P134	<p>Salvage ART regimens based on a combination of an integrase inhibitor and doravirine in heavily antiretroviral-treated people living with HIV <i>Irina Ianache, Cristiana Costescu, Miruna Dragne, Gratiela Tardei, Roxana Radoi, Cristiana Oprea (Bucharest, Romania)</i></p>
P135	<p>Similar efficacy, safety and CD4 T-cell increase up to week 96 observed with fostemsavir (FTR)-based regimens in the BRIGHT study and dolutegravir (DTG)-based regimens in the VIKING-3 study in individuals with multidrug-resistant (MDR) HIV-1 <i>Antonella Castagna, Natalia Gregori, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Aftan Dyson, Bryn Jones, Manyu Prakash, Andrew Clark (Milan, Italy)</i></p>

Scientific Posters

Treatment Strategies – Treatment experienced adults (second line and multi-drug resistance studies) (continued)

P136 Virtual	<p>What is the current place for protease inhibitors in people living with HIV? A retrospective single-centre study <i>Ava Diarra, Agnes Meybeck, Vincent Derdour, Maxime Degrendel, Macha Tetart, Emmanuelle Aissi, Nathalie Viget, Laurence Bocket, Enagnon Kazali (Tourcoing, France)</i></p>
P137	<p>Real-life use of bicitegravir/TAF/emtricitabine in a cohort of people with HIV with a high burden of comorbidities and a history of advanced HIV disease <i>Andrea De Vito, Giulia Moi, Giuseppe Conti, Benedetto Maurizio Celesia, Serena Spampinato, Andrea Marino, Claudia Cali, Maria Antonietta Di Rosolini, Laura Corda, Vincenzo Raimondo, Giovanna Sanna, Goffredo Angioni, Giuseppe Nunnari, Giordano Madeddu (Sassari, Italy)</i></p>
P138	<p>Bicitegravir's effect on persistent low level viraemia and immunological response. BELAIR study: a pilot prospective observational study <i>Vasileios Petrakis, Periklis Panagopoulos, Petros Rafailidis, Grigorios Trypsianis, Stavroula Zisaki, Dimitrios Papazoglou (Alexandroupolis, Greece)</i></p>
P139	<p>HIV treatment with maraviroc: forgotten, not needed or still useful? Results from the MIRROR study <i>Andreas Müller, Markus Bickel, Eva Herrmann, Pavel Khaykin, Axel Müller, Gundolf Schüttfort, Christoph Stephan, Annette Haberl (Frankfurt am Main, Germany)</i></p>
P140 Virtual	<p>The virological efficacy of B/F/TAF in people living with HIV who experienced treatment failure: a real-world cohort <i>Min Yin, Ziqing Yuan (Fuyang, China)</i></p>
P141	<p>Early treatment failure with lenacapavir in HIV-2 infection <i>Martin Obermeier, Özlem Yildirim, Robert Ehret, Maher Almahfoud, Dirk Berzow, Bernhard Krüdwagen, Olaf Degen (Berlin, Germany)</i></p>
P142	<p>HIV GRADE drug resistance interpretation web tool update for capsid and post-attachment inhibitors <i>Martin Obermeier, Robert Ehret, Alexander Thielen, Martin Däumer, Björn Jensen, Carina Elsner, Christopher Dächert, Elena Knops, Eva Geringer, Eva Heger, Eva Wolf, Frank Wiesmann, Hauke Walter, Andrea Hauser, Christian Hoffmann, Irene Görzer, Jens Verheyen, Josef Eberle, Karin Metzner, Klaus Korn, Thomas Lengauer, Karolin Meixenberger, Martin Stürmer, Max Münchhoff, Patrick Braun, Stefan Esser, Thomas Klimkait, Rolf Kaiser, Nadine Lübke (Berlin, Germany)</i></p>
P143	<p>Safety and efficacy of switch to bicitegravir/emtricitabine/tenofovir alafenamide fumarate following dual regimen therapy in HIV: insights from the Icona cohort <i>Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, Andrea Giacomelli, Roberto Rossotti, Giacomo Ponta, Nicoletta Bobbio, Alice Ianniello, Antonella Cingolani, Giordano Madeddu, Andrea Antinori, Antonella D'Arminio Monforte (Sassari, Italy)</i></p>

Treatment Strategies – Models of care for ageing/frail populations including virological failure and switching

P144	<p>Safety and efficacy of doravirine plus tenofovir alafenamide/emtricitabine/bicitegravir (TAF/FTC/BIC) in heavily pre-treated patients <i>Ana Moreno, Jose Luis Casado, Maria Jesus Vivancos, Isabel Izuzquiza, Manuel Velez, Fernando Dronda, Javier Martinez, Raquel Ron, Santos Del Campo, Santiago Moreno, Maria Jesus Perez-Elias (Madrid, Spain)</i></p>
------	--

Scientific Posters

Treatment Strategies – Models of care for ageing/frail populations including virological failure and switching (continued)

P145 **Safety and efficacy of dual doravirine plus lamivudine as a switch strategy in HIV patients with metabolic or renal issues**
Ana Moreno, Jose Luis Casado, Manuel Velez, Maria Jesus Vivancos, Isabel Izuzquiza, Javier Martinez, Santos Del Campo, Santiago Moreno, Maria Jesus Perez-Elias (Madrid, Spain)

P146 **Switching to dual therapy in elderly and multi-experienced patients: profile of a reference service in Brazil**
Luisa de Oliveira Pereira, Jorge Casseb, Mariana Monteiro, Ana Paula Rocha Veiga, Najara Ataide de Lima Nascimento, Luisa Caracik de Camargo (São Paulo, Brazil)

Treatment Strategies – Rapid ART initiation

P147 **Impact of NGS-detected viral mutations on HIV viral decay in patients initiating a BIC/TAF/FTC regimen**
Marcello Trizzino, Roberta Gaudiano, Luca Pipitò, Celestino Bonura, Claudia Gioè, Benedetta Romanin, Irene Ganci, Dalila Mimì Arena, Antonio Cascio (Palermo, Italy)

P148 Virtual **Synthesising HIV clinical guidelines on characteristics, challenges and facilitators of rapid initiation of antiretroviral therapy: a rapid scoping review**
Moustafa Laymouna, Kim Engler, Dominic Chu, Nicholas Hickens, Tibor Schuster, Joel Ishak, Bertrand Lebouché (Montreal, Canada)

P149 Virtual **Temporal trends from HIV diagnosis to ART initiation among adults living with HIV in the Asia-Pacific (2013-2023)**
Thinh Vu, Dhanushi Rupasinghe, Vohith Khol, Romanee Chaiwarith, Junko Tanuma, Nagalingeswaran Kumarasamy, Suwimon Khusuwan, I. Ketut Agus Somia, Sanjay Pujari, Man Po Lee, Rohidas T. Borse, Sasisopin Kiertiburanakul, Evy Yuniastuti, Iskandar Azwa, Jun Yong Choi, Hsin-Pai Chen, Rossana Ditangco, Anchalee Avihingsanon, Yasmin Gani, Jeremy Ross, Awachana Jiamsakul (New York, NY, USA)

P150 **HIV-1 infection recency and pre-treatment drug resistance in recently diagnosed individuals in Greater Gaborone, Botswana: a cross-sectional insight to the "Treat All" strategy**
Natasha Onalenna Moraka, Marea Neo Pema, Goitseone Martha Lemogang, Charity Ralegoreng, Theminkosi Milili Shadrack, Patrick Mokgethi, Doreen Ditshwanelo, Segomotso Maphorisa, Modiegi Bridget Mothudi, Wonderful Tatenda Choga, Ontlametse Thato Bareng, Dorcas Maruapula, Terence Mohammed, Sikhulile Moyo, Simani Gaseitsiwe (Gaborone, Botswana)

P151 **Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: a sub-study of the BIC-NOW clinical trial**
Sergio Sequera-Arquelladas, Maria J. Vivancos, David Vinuesa, Antonio Collado, Ignacio De los Santos, Patricia Sorni, Noemi Cabello-Clotet, Marta Montero, Carlos Ramos-Font, Alberto Terrón, Maria J. Galindo Puerto, Onofre Juan Martínez, Pablo Ryan, Mohamed Omar, Helena Albendin-Iglesias, Rosario Javier, Miguel A. López-Ruz, Alberto Romero, Coral García-Vallecillos, Miguel A. Calleja, Carmen Hidalgo-Tenorio (Granada, Spain)

P152 **Multicentre, prospective cohort study of same-day initiation of antiretroviral therapy with BIC/FTC/TAF among antiretroviral-naïve people with HIV**
Yi-Chia Huang, Hsin-Yun Sun, Po-Liang Lu, Po-Lin Chen, Nan-Yao Lee, Sung-Hsi Huang, Chien-Yu Cheng, Shu-Hsing Cheng, Chia-Jui Yang, Hung-Jen Tang, Shih-Ping Lin, Bo-Huang Liou, Yuan-Ti Lee, Chien-Ching Hung (Hsinchu County, Taiwan)

Scientific Posters

Treatment Strategies – Rapid ART initiation (continued)

P153	<p>Examining the rapid initiation of B/F/TAF strategy through a Canadian lens: an HIV transmission modelling approach <i>Kimberly Guinan, Karine Mathurin, Bertrand Lebouché, Jean Lachaine (Montreal, Canada)</i></p>
P154	<p>Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with HIV-1 (PWH): a systematic literature review (SLR) of clinical and patient-reported outcomes (PROs) <i>Jade Ghosn, Jeremy Chow, Monica Gandhi, Miguel Górgolas Hernández-Mora, Aws Al-Hayani, Hansel Tookes, Max Lee, Emily Kaiser, David Malebranche, Fernando Bogнар, Bhumi Gandhi-Patel, Lilli Dai (Paris, France)</i></p>
P155	<p>Same-day initiation with bictegravir/emtricitabine/tenofovir alafenamide: real-life experience from a centralized single-centre model of care for people living with HIV in Croatia <i>Josip Begovac, Iva Lisicar, Vanja Romih Pintar, Sime Zekan (Zagreb, Croatia)</i></p>
P156	<p>Effectiveness and safety of rapid initiating with BIC/FTC/TAF regimen in advanced people with HIV: a real-world study from southwest of China (EVIDENCE study) <i>Yingchun Zhu, Lin Cai, Yin Wang, Buyun Wang (Chengdu, China)</i></p>
P157	<p>Rapid initiation of antiretroviral therapy under the Treat-All policy reduces loss to follow-up and virological failure in routine HIV care settings in China: a retrospective cohort study (2016-2022) <i>Huan Xia, Ping Ma (Tianjin, China)</i></p>
P158 Virtual	<p>Rapid start: evaluating the time to HIV therapy initiation in a tertiary care hospital in Portugal (2020-2023) <i>Tiago Neves, Mariana Lopes, Helena Alves, Cristina Valente (Coimbra, Portugal)</i></p>
P159	<p>Effectiveness and safety analysis of B/F/TAF for rapid initiation of therapy in people with HIV <i>Yuanhong He, Lin Liu, Tongtong Yang, Jinghong Li, Dianxia Cheng, Ruifeng Zhou (Chengdu, China)</i></p>

Treatment Strategies – Adherence

P160	<p>Real-world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support programme in Canada, preliminary results <i>Callahan LaForty, Adenike Adelakun, Ryan Ng, Bo Chen, Maria Esther Perez Trejo, Lidija Latifovic, Simbarashe Mhishi, Joann Ban (Mississauga, Canada)</i></p>
P161	<p>Effectiveness of enhanced adherence counselling among adolescents receiving dolutegravir-containing regimens with detectable viraemia in Cameroon: optimizing virological outcomes in paediatric settings <i>Suzie Moyo Tetang, Yagai Bouba, Alex Durand Nka, Aude Christelle Ka'e, Rachel Kamgaing, Davy Hyacinthe Gouissi, Nelly Kamgaing, Michel Carlos Tommo Tchouaket, Nadine Nguendjoung Fainguem, Annie Nga Motaze, Francis Ateba, Desire Takou, Lum Forgwei, Dominik Guebiapsi Tameza, Cynthia Ayafor, Efakika Gabisa Jeremiah, Michelle A. Abate, Felicite Noukayo, Suzanne Essamba, Alice Ketchaji, Liman Yakouba, Ezechiel Ngoufack Jagni Semengue, Basseck Roland Wome, Agabus Wiadamong, Abdou Gnambi, Etame Naomi-Karell, Aurelie Minelle Kengni Nguoko, Larissa Moko, Junie Flore Yimga, Collins Ambe Chenwi, Grace Beloumou, Sandrine Djupsa, Rita Ekwoke Mejane, Samuel Martin Sosso, Rogers A. Ajeh, Abdelkader Bacha, Patrice Tchendjou, Anne Esther Njom Nlend, Paul Koki Ndombo, Daniele Armenia, Vittorio Colizzi, Francesca Ceccherini-Silberstein, Maria Mercedes Santoro, Alexis Ndjolo, Carlo-Federico Perno, Joseph Fokam (Yaounde, Cameroon)</i></p>

Scientific Posters

Treatment Strategies – Adherence (continued)

P162 Virtual	Factors associated with lost to follow-up (LTFU) on TB treatment at a large volume clinic in Kampala, Uganda <i>Lyness Bitira, Mark Muhumuza, Prisca Mwangi, Patrick Kazooba (Kampala, Uganda)</i>
P163	Global survey to evaluate engagement in care and treatment experiences of people with HIV <i>Xavier Guillaume, Robin Barkins, Marcel Dams, Nomfundo Eland, Maureen Owino, Carlos Saucedo, Yun-Chung Lu, Amina Omri, Alissar Moussallem, Larkin Callaghan, Michael Bogart, Connie Kim, Megan Dunbar (Foster City, CA, USA)</i>
P164 Virtual	Exploring the minimal proportion of days covered (PDC) threshold required for achieving 90% viral suppression in people with HIV in the era of single-tablet regimens <i>Chun-Yuan Lee, Tien-Heng Ku, Yi-Pei Lin, Chia-Yu Tsai, Po-Liang Lu (Kaohsiung City, Taiwan)</i>
P165	Physician attitudes towards anti-retroviral therapy adherence and unmet treatment needs in people with HIV: a real-world survey in Europe and the United States <i>Rebecca Charlton, Will Ambler, Mark Small, Tim Holbrook, Fritha Hennessy (Bollington, UK)</i>
P166	Exploring latent adherence profiles in South African people living with HIV using group-based trajectory modelling <i>Campbell McDuling, Lauren Jennings, Christopher Ferraris, Paul D'Avanzo, Robert H. Remien, Catherine Orrell, Francesca Little (Cape Town, South Africa)</i>
P167	Effectiveness of mobile health technology in improving HIV care continuity and service delivery among sex workers in Sex Workers Outreach Project (SWOP) clinics, Kenya <i>Idah Mirera, Maureen Akolo (Nairobi, Kenya)</i>
P168 Virtual	Health-related quality of life among the people living with HIV in Armenia <i>Tatevik Balayan (Yerevan, Armenia)</i>
P169 Virtual	Determinants of treatment interruptions in tuberculosis patients at Reach Out Mbuya: insights from a 3-year retrospective study <i>Damalie Nakyoumu, Patrick Kazooba, Gertrude Namale, Emmanuel Sendaula, Josephine Kaleebi (Kampala, Uganda)</i>

Clinical Management Considerations – Women

P170	HIV infection in migrant women from sub-Saharan Africa in North East of Italy: a snapshot of a vulnerable population <i>Anna Ferrari, Lolita Sasset, Marco Cola, Claudia Cozzolino, Maria Cristina Rossi, Fabio Rigo, Veronica Del Punta, Angela Londero, Massimiliano Lanzafame, Sandro Panese, Marina Malena, Vinicio Manfrin, Annamaria Cattelan (Padua, Italy)</i>
P171	Women living with HIV: how far to fulfil the gap? <i>Adriana Cervo, Mariachiara Pellegrino, Federica Casari, Cinzia Puzzolante, Giovanni Guaraldi, Cristina Mussini (Modena, Italy)</i>
P172 Virtual	Postpartum care pathway of women living with HIV in the North of France from 2011 to 2021 <i>Noémie Lemeé, Agnès Meybeck, Roxane Vanspranghels Gibert, Maxime Degrendel, Pauline Coulon, Olivier Robineau, Pauline Thill (Tourcoing, France)</i>
P173	CONception to Child-Rearing in the Early Treatment Era (CONCRETE): a qualitative study of the experiences of women living with HIV during pregnancy and motherhood <i>Clara Merlin, Clara Le Saux, Nelly Courvoisier, Jose Damas, Katharine Darling (Lausanne, Switzerland)</i>

Scientific Posters

Clinical Management Considerations – Women (continued)

P174 **Managing menopause in women living with HIV: impact of online medical education on physician knowledge and confidence**
Shanthi Voorn, Alessia Piazza, Gill Adair, Elizabeth Bukusi, Susan Cole-Haley, Shema Tariq (London, UK)

P175 Virtual **Contraceptive methods in women living with HIV after a pregnancy: Condesa's Clinics, Mexico City**
Teresita Cabrera, Marla Toiber, Edgar Pérez, Carlos Nava, Ubaldo Ramos, Ana Karen Soto, Elena Langarica, Adrian Cruz, Paula Viveros, Andrea González (Ciudad de México, Mexico)

P176 Virtual **Prevalence and determinants of HIV sero-positivity among vulnerable older women in rural Uganda: a call for targeted policy interventions**
Gertrude Ddamulira Namale, Emmanuel Sendaula, Hilda Achayo, Silas Masari, Patrick Kazooba, Josephine Kaleebi (Kampala, Uganda)

Clinical Management Considerations – Late presenters

P177 **Effectiveness of dolutegravir and boosted-darunavir three-drug regimens in advanced ART naive: a trial emulation**
Roberta Gagliardini, Andrea Giacomelli, Cristina Mussini, Stephen R. Cole, Jessie K. Edwards, Carmela Pinnetti, Alessandro Raimondi, Spinello Antinori, Silvia Nozza, Valentina Mazzotta, Giulia Marchetti, Sergio Lo Caputo, Andrea Antinori, Alessandro Cozzi-Lepri (Rome, Italy)

P178 **Risk of long-term clinical progression in PWH initiating a first-line ART with advanced HIV disease and failing to have a robust CD4 count response despite viral suppression**
Giulia Marchetti, Camilla Tincati, Alessandro Cozzi-Lepri, Valeria Bono, Alessandro Tavelli, Eugenio Milano, Stefania Piconi, Cecilia Costa, Annalisa Mondì, Andrea Gori, Miriam Lichtner, Andrea Antinori, Francesca Ceccherini-Silberstein, Antonella d'Arminio Monforte, Carlo Federico Perno (Milan, Italy)

P179 **Screening characteristics of participants in an open label, multi-centre, randomized controlled trial investigating integrase inhibitor versus boosted protease inhibitor antiretroviral therapy for late presenters with advanced HIV disease (LAPTOP)**
Georg Behrens, Lambert Assoumou, Jose Arribas, Christine Katlama, Frank Post, Jean Michel Molina, Andrea Antinori, Rafael Micán, Stephane De Wit, Jürgen Rockstroh, Lisa Hamzah, Pere Domingo, Adrian Curran, Montserrat Laguno, Carl Fletcher, Debbie Roberts, Jack Moody, Anton Pozniak, Study Group LAPTOP (Hannover, Germany)

P180 **Late presentation and HIV-1 subtype diversity among Ukrainian migrants newly diagnosed with HIV in Poland**
Milosz Parczewski, Iwona Cielniak, Ewa Siwak, Elżbieta Mularska, Adam Witor, Błażej Rozpłochowski, Bogusz Aksak-Was, Magdalena Witak-Jedra, Aleksandra Szymczak, Bartosz Szetela, Monika Bociągga Jasik, Anna Kalinowska-Nowak, Paweł Jakubowski, Maria Hlebowicz, Elżbieta Jablonowska, Władysław Łojewski, Anita Olczak, Kaja Mielczak, Piotr Zabek (Szczecin, Poland)

P181 **HIV late presentation and advanced HIV disease increased in Latin America during second year of the COVID-19 pandemic**
María Marta Greco, Pedro Zitko, Carlos Beltrán, Ernesto Martínez Buitrago, Alejandro Afani, Jesús Elías Dawaher, Andrea González, Isabel Casseti, Mónica Mantilla, Ana Lucía Tobias, Elena Obieta (La Plata, Argentina)

Scientific Posters

Clinical Management Considerations – Late presenters (continued)

P182	<p>Implementation of HIV teams sustainably improves HIV indicator condition testing rates in hospitals in the Netherlands: the #aware.hiv study</p> <p><i>Carlijn Jordans, Klaskie Vliegenthart-Jongbloed, Kara Osbak, Jaap Hanssen, Marion Vriesde, Jan van Beek, Natasja van Holten, Willemien Dorama, Dorien van der Sluis, Annelies Verbon, Anna Roukens, Casper Rokx (Rotterdam, Netherlands)</i></p>
P183 Virtual	<p>Late HIV diagnosis in a cohort from Buenos Aires: high mortality and burden of HIV-related disease during the first year</p> <p><i>Ana Rodriguez, Victoria Pinto, Julián Vega, Violeta Zulema Ortiz, José Ángel Enrique Barletta, María José Rolón (Ciudad Autónoma de Buenos Aires, Argentina)</i></p>
P184	<p>Assessing the burden of advanced HIV disease among newly diagnosed individuals in three high-volume facilities in Kampala, Uganda: a retrospective study (2021-2023)</p> <p><i>Julia Linda Ainemukama, Wycliff Sekayi, Patrick Kazooba, Gertrude Namale, Emmanuel Sendaula, Josephine Kaleebi (Kampala, Uganda)</i></p>
P185 Virtual	<p>Late HIV diagnosis in low- and middle-income countries (LMIC): opportunities and challenges ahead</p> <p><i>Victoria Pinto, Ana Rodriguez, José Ángel Enrique Barletta, Julián Vega, Violeta Zulema Ortiz, María José Rolón (Ciudad Autónoma de Buenos Aires, Argentina)</i></p>

Clinical Management Considerations – People who inject drugs (PWID)

P186	<p>Exploring potential interactions between intramuscular cabotegravir (CAB)/rilpivirine (RPV) and methadone: a case report</p> <p><i>Pierluigi Francesco Salvo, Gianmaria Baldin, Valentina Iannone, Elena Visconti, Simona Di Giambenedetto (Rome, Italy)</i></p>
P187	<p>The community pop-up clinic (CPC): HIV treatment in vulnerable population of people who use drugs</p> <p><i>David Truong, Shana Yi, Brian Conway, Rossitta Yung, Shawn Sharma (Vancouver, Canada)</i></p>
P188	<p>Switch to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy</p> <p><i>David Truong, Shana Yi, Brian Conway, Rossitta Yung, Shawn Sharma (Vancouver, Canada)</i></p>

Clinical Management Considerations – Transgender people

P189	<p>Transforming HIV care: intramuscular bimonthly cabotegravir and rilpivirine for transgender people with HIV in Spain (RELATIVITY cohort)</p> <p><i>Alberto Díaz de Santiago, Pablo Ryan-Murua, María José Crusells-Canales, Luis Buzón Martín, Patricia Martín-Rico, Otilia Bisbal-Pardo, Víctor Arenas-García, Alfonso Cabello-Úbeda, Miguel Egido-Murciano, Roberto Pedrero-Tomé (Madrid, Spain)</i></p>
------	--

Clinical Management Considerations – Adolescents

P190 Virtual	<p>Low burden of clinically relevant anaemia and thrombocytopenia among adolescents living with HIV receiving tenofovir/lamivudine plus dolutegravir: the CIPHER-ADOLA Study in Cameroon</p> <p><i>Nadine Fainquem Nguendjoung, Bouba Yagai, Rachel Kamgaing, Davy Hyacinthe Gouissi, Aude Christelle Ka'e, Alex Durand Nka, Annie Nga Motaze, Francis Ateba, Alice Ketchaji, Nelly Kamgaing, Michel Carlos Tommo Tchouake, Rogers Ajeh, Calixte Ida Penda, Vittorio Colizzi, Paul Koki Ndombo, Alexis Ndjolo, Carlo-Federico Perno, Samuel Martin Sosso, Joseph Fokam (Yaounde, Cameroon)</i></p>
-----------------	---

Scientific Posters

Clinical Management Considerations – Adolescents

P191	Baseline HIV genotyping in Saudi Arabian population, a multicentre, cross-sectional study <i>Roaa Alosaimi, Batool Ali, Moayad Alqurashi, Reem Almutairi, Ali Alsaeed, Meqbel Alshelawi, Abdullah Alkhalaf, Abdullah Alsubaie, Layla Faqih (Jeddah, Saudi Arabia)</i>
P192	Increasing understanding in transitioning into adult care for adolescents living with HIV: effect of online education on physician knowledge and confidence <i>Shanthi Voorn, Alessia Piazza, Gill Adair, Ann Chahroudi, Caroline J. Foster (London, UK)</i>

Clinical Management Considerations – Paediatrics

P193	HIV drug resistance among children and adolescents with viraemia in Lesotho and Tanzania: a secondary analysis of the GIVE MOVE trial <i>Christof Manuel Schönenberger, Kathrin Haenggi, Isaac Kaumbuthu Ringera, Ezekiel Luoga, Moniek Bresser, Buang Mthobi, Kuena Mokhele, David Sando, Brenda Simba, Mamello Molatelle, Lineo Thahane, Dorcas Mnzava, Robert Ndege, Mosa Molapo Hlasoa, Buntshi Paulin Kayembe, Josephine Muhairwe, Tracy Renée Glass, Thomas Klimkait, Maja Weisser, Niklaus Daniel Labhardt, Nadine Tschumi, Jennifer Anne Brown (Basel, Switzerland)</i>
P194	Tolerability of lopinavir versus dolutegravir for children and adolescents living with HIV (LoDoCA): a prospective cohort study in Lesotho, southern Africa <i>Jacob Blankenberger, Akash Devendra, Meenakshi Bakaya, Tristan Lee, Teresa Steffy, Thithili Makhesi, Jennifer Belus, Nadine Tschumi, Nthuseng Marake-Raleie, Reto Huber, Frédérique Chammartin, Niklaus Labhardt, Jennifer Brown (Basel, Switzerland)</i>
P195	Structured caregiver literacy sessions: a path to 100% viral load suppression among children living with HIV, Matata Hospital experience, Homa Bay County <i>Brian Boit (Homabay, Kenya)</i>

Clinical Management Considerations – Drug-drug interactions

P196	Dolutegravir-based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV-negative controls <i>Rebecca Ryan, Aamirah Mussa, Bame Bame, Mbapi Bapabi, Neo Moshashane, Imogen Mechie, Samuel Ensor, Neo Ndlovu, Shelby Chakona, Selebaleng Simon, Maipelo Tsuaneng, Laura Else, Alieu Amara, Vinay Tatipamula, Laura Dickinson, Saye Khoo, Chelsea Morroni (Gaborone, Botswana)</i>
P197 Virtual	Effect of fluconazole on the pharmacokinetics of ainoovirine in healthy adults <i>Jianfei Huang, Yan Lei, Weiping Cai, Yu Meng, Lei Xiao, Yi Zhao, Weitong Lin, Yaozu He, Hong Qin, Yufang Zheng, Chunyun Zhang, Kaipeng Huang, Linghua Li (Yangzhou, China)</i>
P198	The geriatric assessment and frequency of polypharmacy and severe drug-drug interactions in older adults with HIV in a tertiary care centre in Mexico City <i>Su Jung Choi, Alvaro López-Iñiguez, Yanink Caro-Vega, Virgilio Hernández-Ruiz, José Alberto Ávila-Funes, Rocio Angelica Sánchez-Morales, Melissa Guerrero-Tobias, Karen Aranza Marañón-Solorio, Juan Carlos Franco-Rodríguez, Brenda Eloisa Crabtree-Ramírez, Juan Sierra-Madero (Mexico City, Mexico)</i>
P199 Virtual	Safety and efficacy of pharmacotherapy containing the second-generation integrase inhibitors (INSTIs) and chemotherapy drugs in AIDS-related diffuse large B-cell lymphoma: a single-centre retrospective analysis <i>Jinq Yang (Chengdu, China)</i>

Scientific Posters

Clinical Management Considerations – Drug-drug interactions (continued)

P200 Virtual	Predicting drug-drug interactions between ainoovirine and rifampicin plus isoniazid using PBPK modelling <i>Xianmin Meng, <u>Hong Qin</u>, Yufang Zheng, Chunyun Zhang, <u>Hongzhou Lu</u> (Yangzhou, China)</i>
P201	Tracing the evolution of polypharmacy and drug-drug interactions in people living with HIV <i><u>Victoria Lopez Delhoulle</u>, Li-Cécile Destordeur, Nathalie Maes, Karine Fombellida, Majdouline El Moussaoui, Gilles Darcis (Liège, Belgium)</i>
P202	Concomitant administration of long-acting cabotegravir/rilpivirine and intramuscular antibiotics for the treatment of sexually transmitted infections: no evidence of pharmacodynamic interference <i><u>Roberto Rossotti</u>, Nicholas Brian Bana, Francesco Peracchi, Gabriele Cavazza, Elisa Di Gennaro, Chiara Baiguera, Alessandro Raimondi, Marco Merli, Carlotta Rogati, Federico D'Amico, Maria Cristina Moioli, Massimo Puoti (Milan, Italy)</i>
P203 Virtual	A study on pharmacist antiretroviral stewardship in relation to drug interaction checking within the Genitourinary Medicine and Infectious Diseases (GUIDe) outpatient clinic in St James's Hospital <i><u>Arlene Heekin</u>, Teresa M. Barbosa, Miriam Moriarty, Miriam Coghlan, Colm Bergin (Dublin, Ireland)</i>
P204	Cabotegravir and rilpivirine injectable therapy with concomitant rifampicin treatment for a multidrug-resistant surgical site infection: management of antiretroviral treatment in real world using therapeutic drug monitoring <i><u>Lorenzo Ciullini</u>, Paul Thoueille, Emilie Piet, Laurent Arthur Decosterd, Catia Marzolini, Alexandra Calmy (Geneva, Switzerland)</i>

Cure/post treatment control

P205	Characterising HIV-1 elite controllers within the Italian Icona Cohort: implications for HIV functional cure <i>Francesca Ceccherini-Silberstein, <u>Luna Colaagrossi</u>, Alessandro Tavelli, Omar El Khalili, Stefano Rusconi, Giuseppe Lapadula, Antonella Cingolani, Alessandra Vergori, Andrea Calcagno, Sergio Lo Caputo, Antonella Castagna, Alessandro Cozzi-Lepri, Giulia Carla Marchetti, Carlo Federico Perno, Antonella D'Arminio Monforte (Rome, Italy)</i>
P206	Absence of viral rebound without antiretrovirals after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation: a new case of a potential cure of HIV? <i><u>Olivia Zaegel-Faucher</u>, Céline Boschi, Samir Benkouiten, Hélène Laroche, Maëva Dos Santos, Anne Motte, Faezeh Izadifar-Legrand, Daniel Olive, Philippe Colson, Sylvie Bregigeon-Ronot (Marseille, France)</i>
P207	Characteristics and management of patients with low level viraemia (LLV) in Greece: a multicentre retrospective study <i><u>Lydia Leonidou</u>, Giota Lourida, Konstantinos Protopapas, Chralambos Moschopoulos, Dimitrios Zoulas, Charisis Totsikas, Dimitrios Basoulis, Elpida Mastrogianni, Apostolos Beloukas, Maria Lagadinou, Markos Marangos, Vasileios Papastamopoulos, Antonios Papadopoulos, Mina Psychogiou (Patras, Greece)</i>
P208	VH3810109 (N6LS) administration dose-responsively enhances anti-HIV antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity in ex vivo models <i><u>Michael Keegan</u>, Margaret Gartland, Saikat Chakraborty, Judah Abberbock, Wilson Chen, Paul Wannamaker, Peter Leone, Jan Losos, Richard Dunham (London, UK)</i>

Scientific Posters

Cure/post treatment control (continued)

P209	<p>Perceptions of healthcare professionals, civil society, pharmaceutical industry and decision-makers around the role of Latin America and the Caribbean in seeking HIV cure <i>Natalia Laufer, Gaston Devisich, Gabriela Turk, Fernando Valiente-Echeverria, <u>María Figueroa</u>, Pedro Cahn, Omar Sued, Claudia Cortes, Brenda Crabtree-Ramírez, Isabel Casseti (Buenos Aires, Argentina)</i></p>
P210	<p>Insights to a cure: unique controller phenotypes in the Rotterdam HIV-2 cohort <i><u>Kathryn Hensley</u>, Rob Gruters, Els van Nood, Mariana de Mendonça Melo, Ronald Overmars, Alicja Gorska, Casper Rokx, Cynthia Lungu, David van de Vijver, Thibault Mesplède, Jeroen van Kampen (Rotterdam, Netherlands)</i></p>
P211	<p>Safety and immunogenicity of GS-1966+GS-1144 vaccines in virally suppressed adults living with HIV-1: a phase Ib, randomized, placebo-controlled study <i>Constance A. Benson, Cynthia Brinson, Moti N. Ramgopal, Anthony M. Mills, Edwin DeJesus, Karin Jooss, Pamela M. Odorizzi, Susie S. Y. Huang, Keith Flower, Yongwu Shao, <u>Christiaan R. de Vries</u>, Devi SenGupta (Foster City, CA, USA)</i></p>
P212	<p>Peptide-induced apoptosis of latently infected cells and reduction of the HIV reservoir in people living with HIV: preliminary results of a clinical trial <i><u>Ricardo Sobhie Diaz</u>, Mauro Schechter, Daniel Elbirt, Esmira Naftali, Juliana Maricato, Marcella Vassao de Almeida Baptista, Juliana Galinskas, Danilo Dias, Alessandra Bassini, Nadya Lisovoder, James Hunter, Eynat Finkelshtein (Sao Paulo, Brazil)</i></p>
P213	<p>Perceptions of analytical treatment interruption among people with HIV using antiretroviral therapy in the United States <i>Karine Dube, Sorana Segal-Maurer, Martha Gauthier, Martin Duracinsky, Kathy Vong, Harlow Sharp, Blaise Cureg, Imani Weeks, <u>Kwanza Price</u>, James Jarrett, Caroline Burk (Foster City, CA, USA)</i></p>
P214 Virtual	<p>Relationship between the functionality of HIV-specific T-cell response and HIV persistence: relevance in the context of cure strategies <i>Lucia Baquero, <u>Leonel Cruces</u>, Sofia Stover, Alejandra Urioste, Alejandro Czernikier, Tomás Langer, Yanina Ghiglione, Gabriela Turk, Natalia Laufer (Buenos Aires, Argentina)</i></p>

Opportunistic infections and AIDS defining cancers

P215	<p>Comparative effectiveness of BIC/FTC/TAF versus other ART regimens in patients with AIDS-defining conditions: virological suppression and immunological recovery at 24 and 48 weeks in the ACTUAS II study <i><u>Ignacio Perez Valero</u>, Diana Corona Mata, Angela Camacho Espejo, Marina Gallo, Inmaculada Jarrin, Antonio Rivero Juarez, Alejandro G. García-Ruiz de Morales, Chiara Fanciulli, Luz Martín Carbonero, Sonia Calzado Isbert, Cristina Hernández Gutiérrez, Víctor Asensi, Antonio Rivero Roman (Cordoba, Spain)</i></p>
P216	<p>Trends in HIV diagnoses and AIDS-defining conditions, Croatia 2009-2023 <i>Josip Begovac, Ivana Benković, Sime Zekan, Nina Vrsaljko, <u>Marija Santini</u> (Zagreb, Croatia)</i></p>
P217 Virtual	<p>Residual disease challenge efforts to achieving successful cervical dysplasia treatment in women living with HIV in Botswana <i><u>Patricia Rantshabeng</u>, Nambumba Loide Amundaba, Moses Rugemalila, Alemayehu Eshetu, Lynnette Kyokunda (Gaborone, Botswana)</i></p>

Scientific Posters

Opportunistic infections and AIDS defining cancers (continued)

P218	<p>Evaluation of the new AltoStar® HHV-7/-8 PCR Kit 1.5 RUO for the quantitative detection of HHV-8 DNA in plasma, whole blood and PBMCs</p> <p><i>Martin Obermeier, Özlem Yildirim, David Mwangi, Malik Prentice, Stefan Breuer, Pascal Migaud, Robert Ehret (Berlin, Germany)</i></p>
P219 Virtual	<p>High proportion of circulating CD8+CD28- T cells predicts inferior prognosis in AIDS-related non-Hodgkin lymphoma</p> <p><i>Juanjuan Chen, Jie Peng, Zixin Kang, Xin Tao, Shuting Wu (Guangzhou, China)</i></p>
P220	<p>Pneumocystis pneumonia cases in HIV and non-HIV individuals in a peripheral hospital in Portugal: an 11-year experience</p> <p><i>Gustavo Lemos Correia, Francisco Soares Laranjeira, Raquel Tavares, Filipa de Oliveira Nunes, Liliana Alves, Rita Sérvio, Paulo Rodrigues (Loures, Portugal)</i></p>
P221	<p>Breaking the age and immunological limits: enhancing cancer treatment in people living with HIV with anti-PD-(L)1 therapies</p> <p><i>Sibo Li, Wenjing Wang, Yue Yuan, Xiaojie Huang, Hao Wu (Beijing, China)</i></p>
P222	<p>Cryptosporidiosis in HIV/AIDS patients in Belgrade, Serbia: a single-centre study</p> <p><i>Ivana Gmizic, Zorica Dakic, Ivan Rajkovic, Jovana Ranin, Borko Pavlica, Snezana Jovanovic, Jovan Ranin (Belgrade, Serbia)</i></p>

Clinical pharmacology

P223	<p>Effectiveness of a dual therapy based on DTG/3TC on reduction of the viral reservoir, immune recovery and immune activation compared with a triple antiretroviral therapy based on DTG/TAF/FTC in patients with HIV infection without prior treatment</p> <p><i>Abraham Saborido-Alconchel, María Trujillo-Rodríguez, Ana Serna-Gallego, Esperanza Muñoz-Muela, Inmaculada Rivas-Jeremias, Ana Álvarez-Ríos, Nuria Espinosa, Cristina Roca, Marta Herrero, César Sotomayor, Alicia Gutierrez-Valencia, Luis Fernando López-Cortés (Seville, Spain)</i></p>
P224	<p>Pharmacokinetics of oral islatravir (ISL) plus lenacapavir (LEN) given once weekly in an open-label, active-controlled, phase II study of virologically suppressed people with HIV-1</p> <p><i>Diane Longo, Gillian Gillespie, Michelle Pham, Stephanie Klopfer, Haeyoung Zhang, Ramesh Palaparthy, Angela S. Y. Liu, Randolph P. Matthews, Cyril Llamoso, Elizabeth G. Rhee, Aubrey Stoch, Dhananjay D. Marathe, Ryan Vargo (Rahway, NJ, USA)</i></p>
P225	<p>Assessing the effects of age and polypharmacy on dolutegravir exposure in plasma and the central nervous system</p> <p><i>Brian Ho, Miao Zhang, Scott Letendre, Ronald Ellis, Donald Franklin, Leah Rubin, Anne Bang, Gene Morse, Donald Mager, Nicholas Smith, Qing Ma (Buffalo, NY, USA)</i></p>
P226	<p>Association of adenosine triphosphate-binding cassette transporter G2 (ABCG2) genetic polymorphisms with subjective symptoms and weight gain by bictegravir administration in Japanese HIV-1-infected patients</p> <p><i>Hiroki Yagura, Dai Watanabe, Takao Nakauchi, Kazuyuki Hirota, Takuro Matsumura, Takashi Ueji, Yasuharu Nishida, Munehiro Yoshino, Tomoko Uehira, Takuma Shirasaka (Osaka, Japan)</i></p>

Scientific Posters

Community-based treatment and prevention initiatives, including primary care screening

P227	<p>Is undiagnosed HIV prevalence among MSM in London changing in the era of combination prevention? Data from the Gay Men's Sexual Health Survey, a serial cross-sectional community sample <i>Flavien Coukan, Dana Ogaz, Gary Murphy, Hamish Mohammed, John Saunders, Fiona Burns (London, UK)</i></p>
P228	<p>Immunovirological outcomes in people living with HIV between immigrant and non-immigrant at the Hospital Clinic of Barcelona (2010-2023) <i>Alexy Inciarte, Elizabeth Zamora-Clemente, Leire Berrocal, Berta Torres, Lorena De La Mora, Elisa de Lazzari, Montserrat Laguno, Maria Martinez-Rebollar, Ana González-Cordón, Ivan Chivite, Alberto Foncillas, Julia Calvo, Abiu Sempere, Juan Ambrosioni, Jose Luis Blanco-Arevalo, Jose Maria Miro Meda, Esteban Martinez-Chamorro, Josep Mallolas (Barcelona, Spain)</i></p>
P229 Virtual	<p>The war in Ukraine exacerbates the problem of late HIV detection <i>Tetiana Koval, Liliia Buria, Olena Marchenko, Olga Stetsenko, Tetiana Bajda (Poltava, Ukraine)</i></p>
P230	<p>HIV in a cohort of female sex workers: far to meet 95:95:95 goals <i>María Macarena Sandoval, Mona Loufty, Virginia Zalazar, Agustín Nava, Nadir F. Cardozo, Mariela Ceschel, Marcela Romero, Georgina Orellano, Carina Cesar, Carolina Pérez, Ana Gun, <u>María Inés Figueroa</u>, Adriana Durán, Inés Arístegui, Zulma Ortiz, Pedro Cahn, Sharon Walmsley, Valeria Fink (Buenos Aires, Argentina)</i></p>
P231	<p>Pilot implementation of HIV self-testing in Ghana: analysis of the community-based demand generation approach <i>Ernest Amoabeng Ortsin, Jonathan Tetteh-Kwao Teye, Richard Socrate Adzesi, Kwadwo Koduah Owusu, Anthony Ashinyo, Stephen Ayisi Addo (Accra, Ghana)</i></p>
P232	<p>Factors contributing to pneumococcal, COVID-19 and influenza vaccine uptake among people living with HIV in Belgium: a retrospective study <i>Li-Cécile Destordeur, Victoria Lopez Delhouille, Iraklis Papadopoulos, Karine Fombellida, Majdouline El Moussaoui, Gilles Darcis (Liège, Belgium)</i></p>
P233 Virtual	<p>Reporting standard compliance in publications of mobile application interventions for antiretroviral therapy adherence among people living with HIV <i>Abdulhammed Babatunde, Dimeji Olawuyi, Folashade Olajuwon, Shamsudeen Olatokun, Olutola Awosiku, Isaac Ekundayo (Ibadan, Nigeria)</i></p>
P234	<p>Implementing effective infectious disease screening in syringe service programmes <i>Heather Henderson, Jason Wilson, Bernice McCoy (Tampa, FL, USA)</i></p>
P235	<p>Influence of community-based oral “PrEP” refill model on adherence and retention among adolescents in Homa Bay County, Kenya <i>Electrine Osewe, Seth Kagia (Nairobi, Kenya)</i></p>
P236	<p>The impact of migratory patterns in a HIV care clinic of a tertiary hospital in Portugal <i>Joana Marinho Silva, Gonçalo Cruz, Cristina Valente (Coimbra, Portugal)</i></p>
P237 Virtual	<p>Use of human-centred design to co-develop a digital platform and evaluate its use to drive uptake of HIV pre-exposure prophylaxis (PrEP) among Nigerian youths in Lagos, Nigeria through a pilot intervention study <i>Yusuf Babatunde, Oluwakorede Adedeji, Abdulmumin Ibrahim (Kigali, Nigeria)</i></p>

Scientific Posters

Community-based treatment and prevention initiatives, including primary care screening (continued)

P238 **Missed opportunities of HIV diagnosis and its clinical repercussions on the Portuguese population: a cohort study**
João Lourinho, Maria João Miguel, Frederico Gonçalves, Francisco Vale, Cláudia Franco, Nuno Marques (Almada, Portugal)

P239 **Characterization of chemsex in PrEP users in four hospitals of Buenos Aires, Argentina**
Maria Belen Zorz, Isabel Pastor, Mariana Angelica Kundro, Guillermo Alberto Vilorio, Marina Alonso Serena, Federico Cardozo, Diego Cecchini, Jose Barletta, Iael Altclas, Marcelo Horacio Losso (Ciudad Autonoma de Buenos Aires, Argentina)

P240 **Long-acting therapy (LA): what Italian PLWHIV think about it**
Sandro Mattioli, Leonardo Del Negro, Salvio Cecere (Bologna, Italy)

P241 **HIV and STI checkpoint screening in Kiel: 4 years of screening in a medium-sized regional centre**
Lutz Ohrtmann (Kiel, Germany)

P242 **Check-Mobil: counselling, testing and case management for vulnerable groups in Schleswig-Holstein, Germany**
Konstantin Kandlen, Louisa Glaum, Sylvia Brillat, Angela Stelling, Ursula Hansen, Hildegard Welbers, Sarah Salvador (Kiel, Germany)

P243 **Retaining adolescents with HIV/AIDS in care through targeted youth camps in Kisumu, Kenya**
Annabel Kokeyo, Geri DelaRosa Brooks, Nancy Yienya, Benard Samba, Margret Mburu, Mary A. Guze, Jayne Lewis Kulzer, Michelle Moghadassi (Kisumu, Kenya)

Public health strategies including of policy options

P244 **Nationality and referral sources of people with HIV seeking first consultations: a 13-year retrospective cohort study at the Hospital Clinic of Barcelona**
Elizabeth Zamora-Clemente, Alexy Inciarte, Leire Berrocal, Berta Torres, Lorena De La Mora, Elisa de Lazzari, Montserrat Laguno, Maria Martinez-Rebollar, Ana González-Cordón, Ivan Chivite, Alberto Foncillas, Julia Calvo, Abiu Sempere, Juan Ambrosioni, Jose Luis Blanco-Arevalo, Jose Maria Miro Meda, Esteban Martinez-Chamorro, Josep Mallolas (Barcelona, Spain)

P245 **Modena and Emilia-Romagna HIV surveillance: the application of ECDC HIV Modelling Tool**
Marianna Menozzi, Adriana Cervo, Gianluca Cuomo, Margherita Digaetano, Beatrice Fontana, Alessandra Soffritti, Erika Massimiliani, Vanni Borghi, Giovanni Guaraldi, Cristina Mussini (Modena, Italy)

P246 **Children Of the Cohort study (CHOC): the unseen population behind people living with HIV**
Clara Merlin, José Damas, Olivier Nawej Tshikung, Noémie Wagner, Anna Hachfeld, Andrea Duppenhaler, Marcel Stoeckle, Malte Kohns, Irene A. Abela, Paolo Paioni, Luigia Elzi, Lisa Kottanattu, Patrick Schmid, Christian R. Kahlert, Katharina Kusejko, Pierre Alex Crisinel, Pascal Pellegrino, Matthias Cavassini, Katharine Darling (Lausanne, Switzerland)

P247 **Assisted partner notification for HIV: a qualitative study in Cape Town, South Africa**
Alison Swartz, Jennifer Nyawira Githaiga, Shehani Perera (Cape Town, South Africa)

P248 **The benefits of free counselling and testing for HIV and STIs in Zurich, Switzerland: a cross-sectional study**
Leonie Arns-Glaser, Andrea Farnham, Jan S. Fehr, Benjamin Hampel (Zurich, Switzerland)

Scientific Posters

Public health strategies including of policy options (continued)

P249	<p>Understanding knowledge and attitudes regarding HIV amongst secondary care healthcare professionals in the United Kingdom: a national survey <i>Moses Shongwe, Michael Brady, Daniel Clutterbuck, Alyscia Curtis, Hilary Curtis, Nadi Gupta, Claire Hutton, Neal Marshall, Jane Nicholls, Hajra Okhai, Joel Paparello, Melissa Perry, Laura Waters, John White (London, UK)</i></p>
P250	<p>Migration as a driver of change in characteristics of new referrals of people living with HIV in a tertiary hospital in Lisbon, Portugal <i>Pedro Leal, Constança Antunes, Margarida Almeida, João Borralho, Sofia Rocha, Ana Cláudia Miranda, Teresa Baptista, Kamal Mansinho (Lisboa, Portugal)</i></p>
P251	<p>Transmitted drug resistance to antiretroviral therapy: interim analysis from a cross-sectional study including 11 healthcare centres in Chile <i>Maria Elena Ceballos, Cinthya Ruiz-Tagle, Felipe Castañeda, Marcela Ferrés, Angélica Domínguez de Landa, Manuel Espinoza, María Elvira Balcells (Santiago, Chile)</i></p>
P253	<p>CHildren Of the Cohort study (CHOC): exploring parenting desire among people living with HIV in Switzerland <i>Clara Merlin, José Damas, Olivier Nawej Tshikung, Noémie Wagner, Anna Hachfeld, Andrea Duppenhaler, Marcel Stoeckle, Malte Kohns, Irene A. Abela, Paolo Paioni, Luigia Elzi, Lisa Kottanattu, Patrick Schmid, Christian R. Kahlert, Katharina Kusejko, Pierre Alex Crisinel, Pascal Pellegrino, Matthias Cavassini, Katharine Darling (Lausanne, Switzerland)</i></p>
P254	<p>Public knowledge, views, perceptions and attitudes towards HIV and people living with HIV in Switzerland: results of a national survey <i>Thomas Grabinger, Marlon Gattiker, David Haerry, Corinna Oberle, Dominique Braun, Katharine Darling (Zug, Switzerland)</i></p>
P255	<p>Once HIV knowledge is addressed: HIV-stigma from the perspective of healthcare professionals working in HIV facilities in French-speaking Switzerland <i>Clara Le Saux, Ingrid Gilles, David Jackson-Perry, Ellen Cart-Richter, Olivier Nawej Tshikung, Katharine Darling (Lausanne, Switzerland)</i></p>
P256 Virtual	<p>Undetectable = Untransmittable, are we transmitting the message correctly? <i>Natalia Laufer, Lorena Abusamra, Leonel Cruces, María José Rolón, Alicia Sisto (Buenos Aires, Argentina)</i></p>
P257	<p>Opt-out blood borne virus (BBV) testing in emergency medicine (EM) in a low prevalence setting <i>Daniela Brawley, Pauline Dundas, Lisa Allerton, Noha El Sakka, Gareth Patton (Aberdeen, UK)</i></p>
P258	<p>U=U: awareness and impact on the quality of life in PWH; experience of a Greek HIV unit <i>Konstantinos Protopapas, Onisiphoros Neophytou, Charalampos D. Moschopoulos, Georgios Zampetas, Konstantinos Thomas, Dimitra Kavatha, Antonios Papadopoulos (Athens, Greece)</i></p>
P259	<p>Persistent HIV related stigma in Germany across different origins: findings from university hospital study <i>Anna Koval, Maher Almahfoud, Hanna Matthews, Angela Buchholz, Sanna Higgen, Anja-Dorothee Huefner, Friederike Theresia Marie Hunstig, Luise Roggelin, Sabine Jordan, Stefan Schmiedel, Olaf Degen (Hamburg, Germany)</i></p>
P260 Virtual	<p>Use of participatory approach in developing interventions for HIV prevention in Africa <i>Abdulhammed Babatunde, Yusuf Babatunde, Adedeji Oluwakorede (Ibadan, Nigeria)</i></p>

Scientific Posters

Public health strategies including of policy options (continued)

P261	The attitudes towards providing care for people living with HIV among healthcare workers in Poland <i>Filip Fijolek, Martyna Cholewik, Carlo Bienkowski, Justyna D. Kowalska, Agata Skrzat-Klapaczynska (Warsaw, Poland)</i>
P262	Outcomes, public health responses, lessons learned and current status of the HIV outbreak (10 year overview) <i>Becky Metcalfe, Sharon Hutchinson, Andrew McAuley, Daniel Carter, Julie Craik, S. Erica Peters (Glasgow, UK)</i>
P263	Estimating return on investment (ROI) with increased utilisation of HIV pre-exposure prophylaxis (PrEP) among key populations in France <i>Turgay Ayer, Emir Gursel, Mert Edali, Claire Idelovici-Marchal, Elias Benabadji, James Jarrett, Dylan Mezzio (Foster City, CA, USA)</i>

Cost and cost-effectiveness

P264	Cost-effectiveness and public-health impact of cabotegravir long-acting injectable for HIV pre-exposure prophylaxis in Canada <i>Adenike Adelakun, Michael Dolph, Emily Matthews, Alan Oglesby, Kelly Campbell, Ashley Davis, Janine Xu, Isabelle Hardy, Natalya Danchenko, Sarah-Jane Anderson (Mississauga, Canada)</i>
P265 Virtual	The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men at high risk of HIV acquisition in eight Latin American countries <i>Jamile Ballivian, Leandro Pastori, Elena Lazo, Carolina Moreno, Camila Volij, Velenn Penini, Adrian Santoro, Santiago Esteban, Adolfo Rubinstein, Federico Augustovski, Andres Pichon-Riviere, Sebastian Garcia-Marti (Buenos Aires, Argentina)</i>
P266 Virtual	Economic estimation of the management of neuropsychiatric events in people with HIV in real life <i>Juan Tiraboschi, Alvaro Mena-de-Cea, Jesus Troya Garcia, Antonio Castro, Pilar Cabrera, Neus Vidal-Vilar (Barcelona, Spain)</i>
P267 Virtual	Cost-effectiveness analysis of ainoovirine versus efavirenz in HIV population initiating first-line combination antiretroviral therapy <i>Chenlu Yang, Yuanqi Mi, Yuhong Zeng, Feng Cheng, Yufang Zheng, Chunyun Zhang, Hong Qin, Huatang Zeng, Mengge Zhou (Yangzhou, China)</i>

Models of care: evaluation of ARV delivery and coverage

P268	Is continuum of care for HIV and hepatitis C possible during war migration: Five Times Ninety project <i>Justyna Kowalska, Olena Samsonova, Sergii Antoniak, Bartłomiej Matlosz (Warsaw, Poland)</i>
P269	Sociodemographic factors influencing retention in care among people with HIV immigrants at Hospital Clinic of Barcelona: a 12-year retrospective cohort study <i>Alexy Inciarte, Elizabeth Zamora-Clemente, Leire Berrocal, Berta Torres, Lorena De La Mora, Elisa De Lazarri, Montserrat Laguno, Maria Martinez-Rebollar, Ana Gonzalez Cordón, Alberto Foncillas, Ivan Chivite, Julia Calvo, Abiu Sempere, Juan Ambrosioni, Jose Luis Blanco-Arevalo, Jose Maria Miro Meda, Esteban Martinez-Chamorro, Josep Mallolas (Barcelona, Spain)</i>
P270 Virtual	Model of remote HIV linkage to care at the AIDS centre: utilising the EECA region as an example <i>Dmitrii Korenev, Kirill Barskiy (Moscow, Russian Federation)</i>

Scientific Posters

Models of care: evaluation of ARV delivery and coverage (continued)

P271	Free HIV drugs as a key tool against the HIV pandemic: a systematic review <i>Benoît Lemire, Melissa Doutre, Marie-Pier Godin, Iliya Dmitriev, Amy Bergeron, Lucie Blais, Ana Paula Bruno Pena Gralle (Montreal, Canada)</i>
P272	Changes in the ART coverage and viral suppression from 2020 to 2022 in Kyiv, Ukraine <i>Olga Fursa, Joanne Reekie, Wendy Bannister, Larysa Hetman, Alina Kryshchuk, Olena Starychenko, Nana Hrytsaiuk, Inna Khodus, Alla Nyzhnyk, Viktoriia Rakhuba, Maryna Kovalevska, Olena Valdenmaier, Jens Lundgren, Lars Peters (Copenhagen, Denmark)</i>
P273	The impact of migratory patterns in HIV profile: an analysis of genotype and resistance mutations of the migrant population in a tertiary hospital <i>Gonçalo Pereira Cruz, Joana Marinho Silva, Cristina Valente (Coimbra, Portugal)</i>
P274	BIC/TAF/FTC in treatment-naive PLWH: the experience of a centre <i>Constança Antunes, Sofia Rocha, Andreia Meseiro, Margarida Almeida, Marta Almeida, Dina Mendes, Ana Cláudia Miranda, Teresa Baptista, Kamal Mansinho (Lisbon, Portugal)</i>
P275	Successful and practical model of care targeting disengaged people living with HIV: the Oak Clinic experience at Russells Hall Hospital in Dudley, United Kingdom <i>Adel Shoukry (Dudley, UK)</i>
P276	A patient survey to explore why patients 'Did Not Attend' in a large inner-city HIV service <i>Wai Lin Htun, Anna Garner (Manchester, UK)</i>

Co-morbidities and complications of disease and/or treatment – Ageing and frailty

P277	Comparison of four frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study) <i>Clotilde Allavena, Diane Abulizi, Hubert Blain, Valérie Adriantsoanirina, Sophie Abgrall, Marina Karmochkine, Christine Katlama, Miresta Previlon, André Cabie, Fabrice Bonnet, Laurence Meyer, Alain Makinson (Nantes, France)</i>
P278	Acceptability and feasibility of digital assessment of falls risk, frailty and mobility impairment using wearable sensors in PLWH as part of HIV care <i>Claire Norcross, Inayat Khan, Tom Levett, Birgit Barbini, Lucy Campbell, Leigh McQueen, Elizabeth Hamlyn, Jaime Vera (Brighton, UK)</i>
P279	Antiretroviral therapy, comorbidities and concomitant medication in people with HIV aged over 75 years in one centre in London, UK <i>Maithili Varadarajan, Kareemah Kannike, Ankita Sahni, Yaser Al-Shakarchi, Nadia Naous, Modest Nwanbila, Nicolo Girometti, Timothy Tong, Marta Boffito (London, UK)</i>
P280	The virtual care experience for persons living with HIV during the COVID pandemic <i>Sharon Walmsley, Marina Klein, Majid Nabipoor, Valerie Martel-Laferrriere, Mona Loutfy, Curtis Cooper, Marie-Louise Vachon, Bryan Boyachuk, Pamela Aldebés (Toronto, Canada)</i>
P281	Association between low skeletal muscle mass and lung function decline in people with HIV <i>Katrine Munk, Moisés Alberto Suarez-Zdunek, Rikke Krabek, Louise Bering, Casper Simonsen, Klaus Fuglsang Kofoed, Andreas Fuchs, Lars Valeur Køber, Thomas Benfield, Sisse Rye Ostrowski, Andreas Dehlbæk Knudsen, Susanne Dam Nielsen (Copenhagen, Denmark)</i>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Ageing and frailty (continued)

P282 **Evaluation of T-cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study**
Matteo Vassallo, Michel Ticchioni, David Chirio, Ami Sadou, Eric Cua, Carole Ceppi, Sara Ferrando, Alissya Naqvi, Bernard Prouvost-Keller, Sommani Mangin-Ratana, Leslie Ameil, Maeva Godemert, Michel Carles, Jacques Durant (Cannes, France)

Co-morbidities and complications of disease and/or treatment – Cardiovascular/metabolic including weight gain

P283 **Risk of hypertension in treatment-naïve people with HIV (PWH) in the US receiving integrase strand inhibitors (INSTIs) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or tenofovir alafenamide (TAF) versus non-TAF-based regimens: pooled analysis of blood pressure data from five clinical trials**
Priscilla Y. Hsue, Laura Waters, Chloe Orkin, Juan Manuel Tiraboschi, Anchalee Avihingsanon, Andrea Marongiu, Andrew Whiteman, Yuan Tian, Carrie M Nielson, Keith Aizen, Cal Cohen, Jason T. Hindman, Jürgen K. Rockstroh (San Francisco, CA, USA)

P284 **Two-fold increased risk of cardiovascular events in people with multidrug-resistant HIV: data from the PRESTIGIO Registry**
Tommaso Clemente, Sara Diotallevi, Davide Minisci, Antonio Di Biagio, Riccardo Lolatto, Letizia Attala, Giovanni Cenderello, Alessia Siribelli, Camilla Muccini, Sergio Lo Caputo, Marcello Tavio, Rebecka Papaioannu Borjesson, Andrea Giacomelli, Antonella Castagna, Vincenzo Spagnuolo (Milan, Italy)

P285 **Incident hypertension with antiretroviral therapy: real-world evidence from the OPERA cohort**
Philip C. Lackey, Laurence Brunet, Jennifer S. Fusco, Gerald Pierone Jr, Michael B. Wohlfeiler, Douglas T. Dieterich, Cassidy E. Henegar, Vani Vannappagari, Bryn Jones, Annemiek de Ruiter, Gregory Fusco (Durham, NC, USA)

P286 **Evaluation of cardiovascular disease amongst adults with perinatally acquired HIV**
Merle Henderson, Vibeke Klastrup, Salwa Ahmad, Jessica Glenn, Sara Ayres, Hana Jadayel, Paula Seery, Caroline Foster, Sarah Fidler (London, UK)

P287 **Evaluation of changes in Systematic Coronary Risk Evaluation 2 (SCORE2) in experienced people with HIV switching to DOR/3TC/TDF: real-world data from DOROTEA multicentre cohort**
Valentina Iannone, Alberto Borghetti, Andrea Giacomelli, Davide Moschese, Filippo Lagi, Massimiliano Fabbiani, Andrea Rabbione, Giuseppe Formica, Francesca Lombardi, Chiara Papalini, Andrea Tommasi, Daniela Francisci, Andrea De Vito, Giordano Madeddu, Maria Vittoria Cossu, Simona Di Giambenedetto, Arturo Ciccullo (Rome, Italy)

P288 **Cabotegravir and rilpivirine reduce the risk of developing metabolic syndrome**
Martina Ranzenigo, Sara Diotallevi, Riccardo Lolatto, Hamid Hasson, Silvia Nozza, Flavia Badalucco Ciotta, Maria del Carmen Garcia Martearena, Ilaria Mainardi, Gaia Catalano, Antonella Castagna, Camilla Muccini (Milano, Italy)

P289 **Incidence of metabolic syndrome in people with HIV in Italy who started ART since 2008: data from the ICONA cohort**
Elena Bruzzesi, Alessandro Tavelli, Romina Salpini, Anna Carraro, Marta Camici, Chiara Papalini, Gregorio Recchia, Carmen Rita Santoro, Maria Vittoria Cossu, Alessandra Guida, Annalisa Mondì, Giulia Marchetti, Giovanni Guaraldi, Antonella D'Arminio, Silvia Nozza (Milan, Italy)

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Cardiovascular/metabolic including weight gain (continued)

P290	<p>The effect of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) on whole-body insulin sensitivity in volunteers without HIV</p> <p><i>Joseph Heskin, Roya Movahedi, Sujin Kang, Ruth Byrne, Krestine Elecito, Perrine Gridel, Paola Marchesani, Graeme Moyle, Ana Milinkovic, Marta Boffito (London, UK)</i></p>
P291	<p>Significant impact of previous major cardiovascular events (MACEs) and viraemia on risk of new MACEs in people living with HIV on antiretroviral therapy</p> <p><i>Caterina Candela, Alessia Siribelli, Tommaso Clemente, Riccardo Lolatto, Michele Bellomo, Hamid Hasson, Vincenzo Spagnuolo, Antonella Castagna, Silvia Nozza, Camilla Muccini (Milan, Italy)</i></p>
P292 Virtual	<p>Improved uric acid metabolism in virologically suppressed people with HIV-1 switching to tenofovir DF-containing, ainoovirine-based compared to tenofovir alafenamide-containing, boosted elvitegravir-based antiretroviral regimen: the secondary analyses of 48-week results of the SPRINT trial, a randomised, active-controlled phase III study</p> <p><i>Ping Ma, Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Fujie Zhang, Hao Wu, Weiping Cai, Wan Wan, Heliang Fu, <u>Hong Qin</u> (Yangzhou, China)</i></p>
P293	<p>Cytomegalovirus antibodies and coronary artery disease in people with HIV</p> <p><i>Moises Alberto Suarez-Zdunek, Andreas Dehlbæk Knudsen, Andreas Fuchs, Nikolai Søren Kirkby, Thomas Benfield, Jan Gerstoft, Marius Trøseid, Lars Valeur Køber, Klaus Fuglsang Kofoed, Susanne Dam Nielsen (Copenhagen, Denmark)</i></p>
P294	<p>N6-methyladenine DNA and ABCA1 methylation association with coronary atherosclerosis in asymptomatic people with HIV with low-intermediate cardiovascular risk</p> <p><i>Jose I Bernardino, Regina Dalmau, Diego Rodriguez-Torres, Gabriel Saiz-Medrano, María Fernandez-Velilla, Inmaculada Pinilla, Javier Rodriguez-Centeno, Andres Esteban-Cantos, Tatiana Mata, Carmen Ramos, Berta Rodes, Miriam Estebanez (Madrid, Spain)</i></p>
P295	<p>Metabolic syndrome among people living with HIV (PLWH) in a specialist HIV clinic in London</p> <p><i>Yomna Gharib, Irfaan Maan, Manik Kohli, Emmi Suonpera, Fowsiya Nur, Anya MacLaren, James Mason, Laura Waters, Richard Gilson, Sarah Pet, Alejandro Arenas-Pinto (London, UK)</i></p>
P296	<p>Prevalence of metabolic syndrome in people living with HIV and its relationship with fatty liver and cardiovascular risk</p> <p><i>Adrian Rodriguez, Ignasi Merino, Aroa Villoslada, Patricia Sorni, Marta Molero, Araceli Serrano, Andrea Salom, Francisco Homar, Antoni Payeras (Palma, Spain)</i></p>
P297	<p>Cardiovascular disease risk according to SCORE2 and the potential need for cholesterol and blood pressure lowering therapy in persons with HIV without established cardiovascular disease, Croatia</p> <p><i>Josip Begovac, Vanja Romih Pintar, Sanja Belak Škugor, Ivana Benković, Ivana Javorić, <u>Sime Zekan</u> (Zagreb, Croatia)</i></p>
P298	<p>Online education yields significant gains in physicians' knowledge of the complexities of cardiometabolic disease in people living with HIV</p> <p><i>Shanthi Voorn, Alessia Piazza, Gill Adair, Patrick Mallon, Carlos Diego Malvestutto, Esteban Martinez (London, UK)</i></p>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Cardiovascular/metabolic including weight gain (continued)

P299	<p>Carotid intima-media thickness, dyslipidaemia, high cardiovascular risk and real-life prescriptions of statins among people living With HIV enrolled in Archi Prevaleat cohort <i>Benedetto Maurizio Celesia, Salvatore Martini, Elena Delfina Ricci, Sergio Ferrara, Laura Galli, Addolorata Masiello, Alessandra Tartaglia, Michele Salvatore Paternò Raddusa, Rosa Basile, Antonella Castagna, Paolo Maggi (Catania, Italy)</i></p>
P300	<p>Association between high sensitivity troponin and NT-pro brain natriuretic peptide and peripheral arterial disease in people living with HIV <i>Thomas Holtveg, Anne Marie Reimer Jensen, Ask Bock, Moises Alberto Suarez-Zdunek, Andreas Dehlbæk Knudsen, Børge Nordestgaard, Shoaib Afzal, Thomas Lars Benfield, Sisse Rye Ostrowski, Tor Biering-Sørensen, Ruth Frikke-Schmidt, Susanne Dam Nielsen (Copenhagen, Denmark)</i></p>
P301	<p>Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of weight Gain in naïve people living with HIV of Asian Origin (DRAGON study) <i>Jang-Pin Chen, Tsung-Chia Chen, Wen-Hsin Hsih, Mao-Song Tsai, Chia-Jui Yang, Shu-Hsing Cheng, Yi-Chun Lin, Ping Ma, Qingxia Zhao, Meiyin Zou, Yi-Wen Wu, Miao-Hui Huang, Wang-Huei Sheng, Chien-Yu Cheng (Taoyuan, Taiwan)</i></p>
P302	<p>Evaluating the cardiovascular risk and the achievement of target levels in low-density lipoprotein cholesterol in PLWH: insights from the DUALIS study <i>Florian Voit, Sven Breitschwerdt, Annamaria Balogh, Helen Bidner, Silvia Egert-Schwender, Christoph Boesecke, Laura Wagner, Eva Wolf, Christoph Spinner (Munich, Germany)</i></p>
P303	<p>Prevalence and cardiovascular risk assessment in HIV patients: comparison between SCORE2 and REGICOR scales <i>Estefanía Díaz Martín, Inês Cachapa Viera, Sonia Calzado Isbert, María Del Carmen Navarro Saez, Marc Pedrosa Aragón, Marta Navarro Vilasaró (Barcelona, Spain)</i></p>
P304	<p>A novel approach to weight loss: bringing I-SatPro into the HIV clinic <i>Eleanor Hamlyn, Jorge Ferreira, Sarah Edwards, Tricia Tan, Saira Hameed, Fiona Burns (London, UK)</i></p>
P305 Virtual	<p>Favourable cholesterol profile in virologically suppressed people with HIV-1 switching to tenofovir DF-containing, ainoovirine-based compared to tenofovir alafenamide-containing, boosted elvitegravir-based antiretroviral regimen: normocholesterolemic subgroup analyses of the SPRINT trial, a randomised, active-controlled phase III study <i>Weiping Cai, Ping Ma, Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Fujie Zhang, Hao Wu, Wan Wan, Heliang Fu, Hong Qin (Yangzhou,, China)</i></p>
P306	<p>Immune and metabolic profile in people living with HIV initiating emtricitabine/tenofovir alafenamide/bictegravir <i>Nicola Squillace, Elena Delfina Ricci, Paolo Maggi, Lucia Taramasso, Barbara Menzaghi, Giuseppe Vittorio De Socio, Eleonora Sarchi, Stefania Piconi, Giovanni Francesco Pellicanò, Giordano Madeddu, Alessandra Bandera, Salvatore Martini, Benedetto Maurizio Celesia, Giancarlo Orofino, Sergio Ferrara, Emanuele Pontali, Maria Aurora Carleo, Elena Salomoni, Giovanni Cenderello, Antonio Cascio, Goffredo Angioni, Katia Falasca, Olivia Bargiacchi, Antonio Di Biagio, Paolo Bonfanti (Monza, Italy)</i></p>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Malignancies: non-AIDS defining

P307	<p>Outcomes after the most common cancers in people with HIV <i>Alisa Timiryasova, Lauren Greenberg, Pere Domingo, Philip E Tarr, Alexander Egle, Charlotte Martin, Cristina Mussini, Ferdinand Wit, Antonella Cingolani, Jörg Janne Vehreschild, Antonella Castagna, Kathy Petoumenos, Caroline Sabin, Wafaa El-Sadr, Fabrice Bonnet, Jens Lundgren, Martina Botanelli, Sean Hosein, Christina Carlander, Alain Amstutz, Katharina Grabmeier-Pfistershammer, Harmony Garges, Andrea Marongiu, Lital A Young, Lars Peters, Lene Ryom (Copenhagen, Denmark)</i></p>
P308	<p>High burden of non-AIDS defining malignancies among adults with HIV in Thailand, 1996-2023 <i>Teton Avihingsanon, Rin Indarodom, Pathaitorn Damtham, Farsai Chiewbangyang, Win Min Han, Jiratchaya Sophonphan, Haymar su Lwin, Anchalee Avihingsanon, Napa Parinyanitikul (Bangkok, Thailand)</i></p>
P309	<p>Screening for anal precancerous lesion and cancer in Japan <i>Naokatsu Ando, Daisuke Mizushima, Misao Takano, Hiroshi Kitamura, Daisuke Shiojiri, Seitaro Abe, Akira Kawashima, Ryo Kuwata, Takato Nakamoto, Takahiro Aoki, Shinichi Oka, Hiroyuki Gatanaga (Tokyo, Japan)</i></p>
P310	<p>Effectiveness of trichloroacetic acid for the treatment of HPV-related anal high-grade squamous intraepithelial lesions <i>Jaime Vega-Costa, Ana Silva-Klug, Mónica Sánchez, Loris Trenti, Maria Saumoy (Hospitalet de Llobregat, Spain)</i></p>
P311	<p>Higher prevalence of high-risk HPV genotypes and lesions in the youngest: do IANS guidelines align with clinical findings? <i>Elena Bruzzesj, Sara Diotallevi, Federica Gandini, Riccardo Lolatto, Massimo Cernuschi, Caterina Candela, Angelo Roberto Raccagni, Flavia Passini, Andrea Marco Tamburini, Roberto Burioni, Antonella Castagna, Silvia Nozza (Milan, Italy)</i></p>
P312	<p>Cancers in people living with HIV: an observational study in the cohort of Modena over 27 years <i>Federica Prandini, Marianna Menozzi, Federica Casari, Deborah Lusetti, Beatrice Fontana, Martina Ricciardetto, Elena Ghidoni, Filippo Calandra, Elena Martini, Giovanni Guaraldi, Cristina Mussini (Modena, Italy)</i></p>
P313	<p>Diagnostic accuracy of non-invasive markers for biopsy-proven high-grade anal dysplasia <i>David Chromy, Steffi Silling, Alexander Kreuter, Anja Potthoff, Nathalie Judith Auer, Dirk Schadendorf, Ulrike Wieland, Stefan Esser (Vienna, Austria)</i></p>
P314	<p>High-resolution anoscopy referral rates when adopting IANS consensus guidelines for anal cancer screening in men who have sex with men living with HIV <i>Christof Stingone, Maria Benevolo, Francesca Rollo, Eugenia Giuliani, Massimo Giuliani, Paolo Giorgi Rossi, Laura Gianserra, Mauro Zaccarelli, Alessandra Latini, Maria Gabriella Donà (Rome, Italy)</i></p>
P315	<p>Shifting patterns and outcomes of malignancies in people living with HIV: a 10-year retrospective study <i>Susana Ramos Oliveira, Mafalda Teixeira Costa, Cristina Soeiro, Clara Bacelar, Clara Batista, Sara Vale Araújo, Mário Guimarães, Constança Azeredo, Frederico Duarte, Sónia Duarte Rocha, Fábio Reis, Eduarda Ruiz Pena, Maria João Gonçalves, Ricardo Correia de Abreu, Sofia Jordão (Senhora da Hora, Portugal)</i></p>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Neurological

P316	<p>Cognitive performance and patient-reported outcomes in older people with HIV in the GEPPPO cohort <i>Federica Barrera, Andrea Calcagno, Andrea Tommasi, Lavinia Patetta, Jovana Milic, Alessandra Coin, Chiara Mussi, Stefano Calza, Benedetto Maurizio Celesia, Samuele Gardin, Domenico Azzolino, Elisa Lenotti, Micol Ferrara, Benedetta Fioretti, Giordano Madeddu, Giancarlo Orofino, Emanuele Focà, Giovanni Guaraldi (Turin, Italy)</i></p>
P317	<p>The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study <i>Saumitro Deb, Jessica Doctor, Jaime Vera, Frank Post, Jasmini Alagaratnam, Patrick W. G. Mallon, Jane Anderson, Laura Waters, Nicki Doyle, Fiona Burns, Memory Sachikonye, Alan Winston, Caroline Sabin (London, UK)</i></p>
P318	<p>Brain functional connectivity changes over 18 months in persons with acute and chronic HIV infection <i>Charalampos D. Moschopoulos, Evangelia Stanitsa, Efstratios Karavasilis, Konstantinos Protopapas, Dimitra Kavatha, Antonios Papadopoulos, Georgios Velonakis, Sokratis G. Papageorgiou, Anastasia Antoniadou (Athens, Greece)</i></p>

Co-morbidities and complications of disease and/or treatment – Renal

P319	<p>Long-term change of renal function among people with HIV who received TAF-containing ART <i>Guan-Jhou Chen, Hsin-Yun Sun, Szu-Min Hsieh, Wang-Hui Sheng, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung (Taoyuan, Taiwan)</i></p>
P320	<p>Reduction in estimated glomerular filtration rate (eGFR) observed with doravirine (DOR) is caused by inhibition of organic cation transporter 2 (OCT2) <i>Yang Li, Xiaoyan Chu, Rosa I. Sanchez, Russ P. Carstens, Mary L. Pisculli, Stephanie Klopfer, Zhi Jin Xu, Rima Lahoulou, Rebeca M. Plank (Rahway, NJ, USA)</i></p>
P321 Virtual	<p>Profiles of cardiac, liver, renal, musculoskeletal, and pancreatic safety in virologically suppressed people with HIV-1 switching to tenofovir DF-containing, ainoovirine-based antiretroviral regimen: the secondary analyses of 48-week results of the SPRINT trial, a randomised, active-controlled phase III study <i>Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Fujie Zhang, Hao Wu, Weiping Cai, Ping Ma, Wan Wan, Heliang Fu, Hong Qin (Yangzhou, China)</i></p>
P322	<p>Kidney transplantation in liver-transplanted HIV-positive recipients with end-stage renal disease: two case reports <i>Daniela Malano Barletta, Nuria Esforzado, Pablo Ruiz, Frederic Cofan, Montserrat Laguno, David Cucchiari, Alejandro Forner, Hugo López, Mireia Musquera, Asunción Moreno, Antonio Rimola, Fritz Diekmann, José María Miró (Barcelona, Spain)</i></p>
P323	<p>Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study <i>Sébastien Gallien, Lambert Assoumou, Jacques Dantal, Anne Hulin, Aida Benalycherif, Raida Ben Rayana, Yasmine Tobbal, Marie Matignon, Giovanna Melica, Clotilde Allavena, Thomas Stehle (Créteil, France)</i></p>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Mental health disorders

P324	Resilience among people with HIV: results from the UK Positive Voices 2022 survey <i>Colette Smith, Janey Sewell, Alex Sparrowhawk, Annegret Pelchen-Matthews, Fumiyo Nakagawa, Fiona Wilson, Tracey Fong, Hannah Kitt, Carole Kelly, Meaghan Kall, Veronique Martin, Adamma Aghaizu, Alison Rodger, Fiona Lampe (London, UK)</i>
P325	Mental health in people with HIV (PWH): patient-reported outcomes in the DUALIS study <i>Eva Wolf, Annamaria Balogh, Florian Voit, Judith Laufenberg, Christoph Boesecke, Christine Koegl, Christoph D Spinner, Andreas Dinkel, of the DUALIS study group on behalf (Munich, Germany)</i>
P326	Anxiety and depression in people living with HIV/AIDS (PLHIV) and their impact on fatigue and health-related quality of life (HRQOL) <i>Pulin Kumar Gupta, Akhil Goyal, Atul Anand (New Delhi, India)</i>
P327	No association of cART and HIV-related parameters with health-related quality of life (HR-QoL) of PLWH: insights from a multidimensional screening <i>Stella Capodiecj, Mauro Zaccarelli, Alessandra Latini, Christof Stingone, Laura Gianserra, Maria Gabriella Donà, Eugenia Giuliani, Valentina Cafaro, Massimo Giuliani (Rome, Italy)</i>
P328 Virtual	Predictors of mortality among tuberculosis patients with mental health disorders: a retrospective study at a national referral mental hospital in Uganda <i>Isaiah Aryatuhg, Patrick Kazooba, Gertrude Namale, Emmanuel Sendaula, Josephine Kaleebi (Kampala, Uganda)</i>
P329 Virtual	Mental health service access barriers and facilitators among people living with HIV: a qualitative study in Georgia <i>Esmā Imerlishvili, Maia Kajaia, Mariam Pashalishvili, Eka Chkhonia, Tamar Zurashvili, Ramesh Raghavan, Mamuka Djibuti (Tbilisi, Georgia)</i>

Co-morbidities and complications of disease and/or treatment – Other

P330	Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) + lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies <i>Dainielle Fox, Gary Blick, Thibault Mesplède, Gustavo Verdier, Mónica Calderón, Chris M. Parry, Richard Grove, Emilio Letang, Julie Priest, Bryn Jones (Durham, NC, USA)</i>
P331	Use of lipid-lowering drugs, even when associated with polypharmacy, reduces risk of hospitalisation in PWH >50 years <i>Jovana Milic, Alessandra Carobbio, Antonia Pugliese, Pierluigi De Cosmo, Lorenzo Federici, Federico Motta, Filippo Calandra Buonaura, Matteo Mantovani, Francesca Gandolfi, Chiara Mussi, Cristina Mussini, Giovanni Guaraldi (Modena, Italy)</i>
P332 Virtual	Penile vascular status in young men living with HIV experiencing erectile dysfunction: a comparative cross-sectional study <i>Giorgio Tiecco, Marco Di Gregorio, Cosimo Colangelo, Andrea Delbarba, Matteo Riva, Carlo Cappelli, Emanuele Focà, Francesco Castelli, Eugenia Quiros-Roldan (Brescia, Italy)</i>
P333	The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeOPle over fifty (POPPY) study over a 3-5 year period <i>Luxsena Sukumaran, Alan Winston, Patrick W. G. Mallon, Frank A. Post, Memory Sachikonye, Marta Boffito, Nicki Doyle, Jaime Vera, Jane Anderson, Fiona M. Burns, Caroline A. Sabin (London, UK)</i>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Other (continued)

P334	<p>Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia <i>Erich Tusch, Lene Ryom, Christian Hoffmann, Olaf Degen, Robert Zangerle, Huldrych Günthard, Ferdinand Wit, Cristina Mussini, Antonella Castagna, Charlotte Martin, Andrea Giacomelli, Jörg Janne Vehreschild, Josip Begovac, Vani Vannappagari, Jim Rooney, Lital Young, Joan Tallada, Justyna Kowalska, Elmar Wallner, Katharina Kusejko, Nadine Jaschinski, Jens Lundgren, Lars Peters, Joanne Reekie (Copenhagen, Denmark)</i></p>
P335	<p>Stigma in older people with HIV: disclosure concerns and self-image do not improve over time in older AGEHIV Cohort Study participants <i>Kevin Moody, Myrthe L. Verburgh, Ferdinand W. N. M. Wit, Sarah Stutterheim, Maarten F. Schim van der Loeff, Peter Reiss, Pythia T. Nieuwkerk, Marc van der Valk (Amsterdam, Netherlands)</i></p>
P336	<p>Prevalence of unmet need for support managing long-term conditions among people with HIV <i>Adamma Aghaizu, Hannah Kitt, Carole Kelly, Alison Brown, Alex Sparrowhawk, Fiona Wilson, Judith Zhou, Meaghan Kall, Alison Rodger, Janey Sewell, Annegret Pelchen-Matthews, Colette Smith, Valerie Delpech, Veronique Martin, Clare Humphreys (London, UK)</i></p>
P337 Virtual	<p>Profile of suicide cases in the Spanish CoRIS cohort between 2004-2022 <i>Julián Olalla, Alfonso Del Arco, Melchor Riera, Joaquim Peraire, Enrique Bernal, Javier De la Torre, Antonia Castillo-Navarro, Lorena Martínez-Fernández, Javier Pérez-Stachowski, Santiago Moreno (Marbella, Spain)</i></p>
P338 Virtual	<p>The clinical utility of targeted screening for liver fibrosis/cirrhosis among people living with HIV (PLWH) <i>Izuchukwu Ezeh, Amy Hardy, Martin Prince, Vincent Lee (Manchester, UK)</i></p>
P339	<p>Patient-reported outcome measures among people with HIV on antiretroviral therapy in Kunming, China <i>Yongmei Jin, Jun Liu, Bo Tian, Chongxi Li (Kunming, China)</i></p>
P340	<p>Virological failure and patterns of resistance-associated mutations in previously untreated HIV-positive participants in the RESINA cohort <i>Smaranda Gliga, Michael Böhm, Nadine Lübke, Alexander Killer, Falk Hüttig, Claudia Müller, Eva Heger, Joachim Büch, Gerd Fätkenheuer, Clara Lehmann, Mark Oette, Martin Hower, Heribert Knechten, Niels Schübel, Stefan Esser, Stephan Schneeweiß, Nazifa Qurishi, Katja Römer, Rolf Kaiser, Tom Luedde, Björn Jensen (Düsseldorf, Germany)</i></p>
P341	<p>Online education yields significant gains in physicians' knowledge of the physical implications of stigma in people living with HIV <i>Shanthi Voorn, Alessia Piazza, Gill Adair, Chloe Orkin, Maile Young Karris (London, UK)</i></p>
P342	<p>Identification of quality-of-life alterations among people living with HIV in Romania: ROCTAVE self-administered questionnaire <i>Oana Sandulescu, Victor Daniel Miron, Irina Magdalena Dumitru, Manuela Arbune, Anca Streinu-Cercel (Bucharest, Romania)</i></p>
P343 Virtual	<p>Anti-retroviral regimen change and its predictors among people living with HIV in Hawassa University Comprehensive Specialized Hospital, southern Ethiopia, retrospective cohort study <i>Endrias Makos Woldesemayat, Wonago Petros, Jaime Vera (Hawassa, Ethiopia)</i></p>
P344	<p>The impact of cART on the intracellular antioxidant capacity in peripheral blood mononuclear cells of people living with HIV <i>Radoslava Emilova, Yana Todorova, Reneta Dimitrova, Victor Manolov, Nina Yancheva, Milena Aleksova, Damian Vangelov, Maria Nikolova (Sofia, Bulgaria)</i></p>

Scientific Posters

Co-morbidities and complications of disease and/or treatment – Other (continued)

P345	<p>Unmasked immune reconstitution syndrome diagnoses among people living with HIV admitted in a low-resource hospital, Homabay, Kenya 2021-2022 <i>Edward Corneleous Odhiambo Okal, Thaddeus Owiti, James Wagude, Gordon Okomo (Homabay, Kenya)</i></p>
------	---

People living with HIV and COVID-19: outcomes

P346	<p>Proteic and mRNA XBB.1.5 SARS-CoV-2 vaccines elicit a close neutralising response against JN.1 in PWH <i>Alessandra Vergori, Giulia Matusali, Eleonora Cimini, Alessandro Cozzi Lepri, Federico Cecilia, Davide Mariotti, Francesca Colavita, Simona Gili, Flavia Cristofanelli, Marisa Fusto, Valentina Mazzotta, Jessica Paulicelli, Roberta Gagliardini, Enrico Girardi, Fabrizio Maggi, <u>Andrea Antinori</u> (Rome, Italy)</i></p>
------	---

P347	<p>No changing incidence of type 2 diabetes in PWH before and after the first wave of the COVID-19 pandemic <i>Alessandra Vergori, Alessandro Tavelli, Sara De Benedittis, Nicola Squillace, Lucia Taramasso, Roberto Rossotti, Eugenia Quiros Roldan, Andrea Santoro, Andrea Calcagno, Simone Lanini, Giuseppe Lapadula, Giovanni Guaraldi, Antonella Castagna, Andrea Antinori, <u>Alessandro Cozzi Lepri</u> (London, UK)</i></p>
------	--

P348	<p>"Don't turn that patient away, they must be seen." A qualitative exploration of the views of London HIV clinical service providers on HIV care engagement challenges (the SHIELD Study) <i>Rageshri Dhairyawan, Shiraaz Sidat, <u>Rebecca Mbewe</u>, Silvia Petretti, Jane Anderson, Vanessa Apea, Sara Papparini, Chloe Orkin (London, UK)</i></p>
------	--

P349 Virtual	<p>SARS-CoV-2 vaccination and coronaviral disease 2019 in virologically suppressed people with HIV-1 previously on NNRTI-based antiretroviral regimen during the pandemic: the secondary longitudinal analysis of the SPRINT study, a multi-centre, randomised, active-controlled phase III trial <i>Hongzhou Lu, Hui Wang, Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Fujie Zhang, Hao Wu, Weiping Cai, Ping Ma, Qingxia Zhao, Hongxia Wei, Wan Wan, Heliang Fu, <u>Hong Qin</u> (Yangzhou, China)</i></p>
-----------------	--

People living with HIV and mpox virus

P350	<p>Mpox clade II in France in 2023-2024: an endemic situation? <i>Mayda Rahi, Sebastien Fouere, Marie Gilbert, Antoine Bachelard, Fabien Taieb, Baptiste Sellem, Florian Herms, Charles Cazanave, Gentiane Monsel, Yazdan Yazdanpanah, Nathan Peiffer-Smadja, <u>Jade Ghosn</u> (Paris, France)</i></p>
------	---

P351	<p>One-year review of mpox in Hong Kong <i><u>Laura Pui Yee To</u>, Ching See Leung, Yau Chung Choi, Alicia Wing Tung Lau, Sophia Sharon Lamb, Daphne Pui Ling Lau, Thomas Shiu Hong Chik, Ki Wai Heather To, Bonnie Chun Kwan Wong, Jacky Man Chun Chan, Owen Tak Yin Tsang (Hong Kong Special Administrative Region, China)</i></p>
------	---

P352	<p>Exploring synergistic social media effects for people with HIV during the mpox epidemic: the evolution of the HIV case manager into a podcaster <i><u>Chung-Ching Shih</u>, Chin-Fang Huang, Wei-Ming Chen (Taipei, Taiwan)</i></p>
------	--

P353	<p>Exploring mpox vaccination uptake and tolerability among individuals living with HIV: a single-centre study in an infectious disease unit in Italy <i>Samuele Gaggioli, Giuseppe Formica, Valentina Petrini, Alessandra Russo Krauss, Costanza Fiorelli, Paola Corsi, Alessandro Di Felice, Costanza Malcontenti, Michele Trotta, Emanuela Francalanci, Giulia Modi, Francesca Costa, Seble Tekle Kiros, Lorenzo Zammarchi, Alessandro Bartoloni, <u>Filippo Lagi</u> (Firenze, Italy)</i></p>
------	---

Scientific Posters

People living with HIV and mpox virus (continued)

P354 **The frequency of scars following mpox: an aftermath of the 2022 outbreak**
David Chromy, Nikolaus Urban, Wolfgang Michael Bauer, Alexander Kreuter, Robert Strassl, Katharina Grabmeier-Pfistershammer (Vienna, Austria)

People living with HIV and sexually transmitted diseases

P355 **Knowledge, attitudes and behaviours in relation to doxycycline post-exposure prophylaxis (dPEP) use amongst attendees and healthcare workers at a large sexual health and HIV service in Ireland**
Amy Keane, Fiona Lyons, Diego Caixeta, Colette Smith, Jean-Michel Molina, Giovanni Villa (Dublin, Ireland)

P356 **Incidence and clearance of high-grade anal squamous intraepithelial lesions in men who have sex with men living with HIV**
Maria Saumoy, Ana Silva-Klug, Jaime Vega, Monica Sánchez, Joao Carmezin, Miguel Angel Pavon, Laia Alemany, Núria Baixeres, Loris Trenti, Sónia Paytubi (Hospitalet de Llobregat, Spain)

P357 **Characterisation of specific T-cell responses to a three-doses nonavalent HPV vaccine schedule in PLWH on ART**
Eeva Tortellini, Mariasilvia Guardiani, Federica Dominelli, Carmen Falvino, Anna Carraro, Sara Corazza, Sara Giovanna De Maria, Silvia Garattini, Blerta Kertusha, Lorenzo Ansaldo, Maria Antonella Zingaropoli, Fabio Mengoni, Cristina Giambi, Cosmo Del Borgo, Raffaella Marocco, Miriam Lichtner (Rome, Italy)

P358 **Study on the prevalence and incidence of dysplasia and HPV infection of the oropharyngeal, cervical and anal mucosa (oropharyngeal) of people with HIV**
Carmen Hidalgo Tenorio, Inmaculada Calle-Gómez, Raquel Moya-Mejias, Mohamed Omar, Javier Lopez Hidalgo, Javier Rodriguez Granges, Carmen Garcia Martinez (Granada, Spain)

P359 **Exploring interest in long-acting antiretroviral injections: perspectives of people living with HIV in Egypt and Saudi Arabia**
Salma M. A. Mansour, Roaa Alosaimi, Heba Fahmy, Ahmed Cordie, Rahma Mohammed, Batool Ali, Ganna Essam Elnahas, Amany A. Salem, Ibrahim Ali Kabbash (Jeddah, Saudi Arabia)

P360 **Treatment of *Mycoplasma genitalium* and detection of macrolide resistance mutations (23S rRNA) in PHIV and HIV-negative individuals**
Elena Suanzes-Martín, María Muñoz-Algarra, Sara De la Fuente-Moral, Ilduara Pintos-Ramos, Natalia Vicente-López, Alberto Díaz de Santiago (Madrid, Spain)

P361 **Antimicrobial resistance pattern in *Neisseria gonorrhoeae* isolates from men having sex with men (MSM): results from the first prospective cohort in Poland**
Bartosz Szetela, Beata Maczynska, Konrad Starzynski, Daria Zareba, Danuta Ruranska-Smutnicka, Anna Sacewicz, Paulina Szuba, Martyna Biala (Wroclaw, Poland)

P362 **Syphilis incidence among HIV-infected MSM and IDUs is as high before and after achieving U=U in Japan**
Hauka Uemura, Daisuke Mizushima, Naokatsu Ando, Takato Nakamoto, Takahiro Aoki, Katsuji Teruya, Hiroyuki Gatanaga (Tokyo, Japan)

P363 **Epidemiological study of the prevalence of STIs and HIV among men who have sex with men in the Russian Federation**
Dmitrii Korenev, Kirill Barskiy (Moscow, Russian Federation)

P364 ***Neisseria gonorrhoeae* (NG) infection in MSM: clinical and microbiological characteristics - culture is essential but provides limited assistance**
Cristina Gómez-Ayerbe, María López-Jódar, Salvador Martin-Cortes, Marina Villalobos, Isabel Perez-Hernández, María Victoria García-López, Rosario Palacios, Jesús Santos (Málaga, Spain)

Scientific Posters

People living with HIV and sexually transmitted diseases (continued)

P365 Virtual	Sexually transmitted infections in virologically suppressed people with HIV-1: the secondary longitudinal analysis of the SPRINT study, a multi-centre, randomised, active-controlled phase III trial <i>Shenghua He, Zhu Chen, Yaokai Chen, Min Wang, Fujie Zhang, Hao Wu, Weiping Cai, Ping Ma, Qingxia Zhao, Hongxia Wei, Hongzhou Lu, Hui Wang, Wan Wan, Heliang Fu, <u>Hong Qin</u> (Yangzhou, China)</i>
P366	Malignant syphilis as the initial manifestation of HIV: a case report <i>Filippo Calandra Buonauro, Marco Visicaro, Antonella Santoro, Cristina Mussini (Modena, Italy)</i>
P367	Syphilis profile in individuals on post-exposure prophylaxis with doxycycline (Doxy PEP) <i>Rosario Palacios, María López-Jódar, Salvador Martín-Cortés, Andrea Prolo, Isabel Ascensión Pérez Hernández, Isabel Viciano, Cristina Gómez-Ayerbe, Jesús Santos (Málaga, Spain)</i>
P368	Acceptability and real-life experience of doxyPEP in MSM at a combined HIV/PrEP clinic in a Southeast Asian university hospital <i>Dariusz Olszyna, Eon Tat Gan, Tiane Le, Sophia Archuleta (Singapore, Singapore)</i>

People living with HIV and tuberculosis

P369	Long-term efficacy of tuberculosis preventive treatment in people living with HIV: a single centre prospective cohort study <i>Napon Hiranburana, Hay Mar Su Lwin, Jiratchaya Sophonphan, Win Min Han, Chuleeporn Khongpetch, Anchalee Avihingsanon (Bangkok, Thailand)</i>
P370	Impact of injection drug use on tuberculosis outcomes in people with HIV: a nationwide cohort study <i>Naila Bugyi-Bozo, Josep M Llibre, Iben Ørsted, Nina Breinholt Stærke, Johanna Åhsberg, Gitte Kronborg, Steffen Leth, Lars Haukali Omland, Niels Obel, Line Dahlerup Rasmussen, Isik Somuncu Johansen, Raquel Martin-Iguacel (Odense, Denmark)</i>
P371	Evaluating tuberculosis prevalence in key populations with advanced HIV diseases in Nigeria <i>Mark Akhiqbe, Roger Abang, Abiye Kalaiwo, Paul Umoh (Uyo, Nigeria)</i>

People living with HIV and viral hepatitis

P373	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve people with both HIV-1 and hepatitis B: 3-year outcomes from ALLIANCE <i>Anchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, Chien-Ching Hung, Sasisopin Kiertiburanakul, Man-Po Lee, Khuanchai Supparatpinyo, Sharline Madera, Hongyuan Wang, Jason Hindman, Taisheng Li (Bangkok, Thailand)</i>
P374	Long-term outcomes of people living with HCV/HIV with advanced hepatic fibrosis treated with direct-acting antivirals: a retrospective study <i>João Matos, Inês Caetano, Flavia Faria, Francisco Novela, António Ludgero Vasconcelos, Josefina Méndez (Porto, Portugal)</i>

People living with HIV and viral hepatitis

P376	Acute/recent infections and reinfections by HCV in MSM with and without HIV in the region of Madrid (ATHENS study) <i>Pablo Ryan, <u>Juan Berenquer</u>, Luis Ramos, Mar Vera, Leire Pérez-Latorre, Ignacio De los Santos, Adriana Pinto, Santos Del Campo, Eva Orviz, Beatriz Alvarez, José Sanz, Pilar Ruiz-Seco, Rafael Torres, Beatriz Brazal, Beatriz López-Centeno, José M. Bellón, Luz Martín-Carbonero, Juan González-García (Madrid, Spain)</i>
------	--

Scientific Posters

People living with HIV and viral hepatitis (continued)

P377 Virtual	HIV/HBV coinfection in Portugal today: data from a multicentric approach <i>Ruben Carvalho, Ana Martins, João Matos, Vanda Castro, Joana Martinez, António Ferreira, Catarina Esteves, Ana Parente, Jorge Velez, Josefina Mendez, Cristina Valente (Coimbra, Portugal)</i>
P378	HCV cure with direct-acting antivirals in HIV/HCV coinfecting patients belonging to key populations <i>Cristiana Oprea, Irina Ianache, Cristiana Costescu, Sebastian Piscu, Sorina Vasile, Luminita Ene, Roxana Radoi, Ionut Popa (Bucharest, Romania)</i>
P379	"What we wanted was what we needed" - collaborative community advocacy for inclusive clinical trials in emerging hepatitis C research: lessons from the EATG Sitges model <i>Rocco Pignata, Ian Hodgson, Giorgio Barbareschi, Apostolos Kalogiannis, Fiona Greenhalgh, Brian West, Sean Hosein, Alain Volny-Anne, Luis Mendão, Memory Sachikonye (Brussels, Belgium)</i>
P380 Virtual	HIV/HCV: barriers to treatment in the era of direct acting antivirals in a low-middle income country <i>Raquel Zhumi, Cruz Molina Neizly, Falak Adriana, Alicia Sisto, Maria Rolon, Natalia Laufer (Buenos Aires, Argentina)</i>
P381 Virtual	The era of DAAs: assessing the patients' characteristics, clinical impact, and emergence of comorbidities in HIV/HCV-coinfecting versus HIV-infected individuals <i>Beatriz Álvarez-Álvarez, Laura Prieto-Pérez, Alberto de la Cuadra-Grande, Miguel Ángel Casado, Alfonso Cabello Úbeda, Aws W. Al-Hayani, Irene Carrillo Acosta, Ignacio Mahillo-Fernández, Miguel Górgolas Hernández-Mora, José M. Benito, Norma Rallón (Madrid, Spain)</i>
P382	Predictors of hepatitis C treatment failure in people living with HIV <i>Alan Sinuhe Medina Valle, Elizabeth Mendoza Portillo, Humberto Gudiño Solorio (Mexico City, Mexico)</i>

People living with HIV and other diseases

P383	Preliminary results of a pilot study to evaluate the usefulness of using patient-reported outcomes (PROs) in the follow-up of patients living with HIV <i>Sara de la Fuente Moral, María Pilar Corrales Rodríguez, Ana Belén Hernández López, Carlos Folguera Olías, Belén Menchén Viso, Miriam Redondo, Victoria Ayala Vargas, María Sainz Guerra, Alberto Díaz de Santiago (Madrid, Spain)</i>
P384	Preferences for a psychosocial intervention based on health and wellbeing coaching, for people living with HIV in a secondary care setting in England, Wales and Scotland: a discrete choice experiment <i>Janey Sewell, Meaghan Kall, Adamma Aghaizu, Alec Miners, Alex Sparrowhawk, Jane Holder, Farai Mukazi, Alison Rodger, Fiona Lampe, Valentina Cambiano (London, UK)</i>
P385	Developing the person-centred needs informed model of care for people with HIV (NICHE) programme: findings from formative qualitative research <i>Vasiliki Papageorgiou, Lucy Cullen, T. Charles Witzel, Flavien Coukan, Alex Sparrowhawk, Jonathan William Shaw, Janey Sewell, Alison Rodger, Fiona Burns, Carl May (London, UK)</i>
P386	Inflammatory biomarkers decay after first-line antiretroviral treatment initiation with dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide. What puts the fire out faster? <i>Analuz Fernandez, Sofia Scevola, Raul Rigo Bonin, Maria Saumoy, Arkaitz Imaz, Daniel Podzamczar, Juan Manuel Tiraboschi (L'Hospitalet de Llobregat, Spain)</i>

Scientific Posters

People living with HIV and other diseases (continued)

P387 Virtual	Assessing the utility of a simple respiratory symptom screening tool in an outpatient population of people with HIV <i>Andrew Read, Rob F. Miller, Fiona M. Burns, Jane Akodu, Sarah Edwards, James Brown, Marc Lipman, Tristan J. Barber (London, UK)</i>
P388	Additional vaccination in PLWH: adherence in a central hospital in Lisbon <i>António Moreno-Marques, Fátima Gonçalves, Zélia Rodrigues Sobral, Fábio Cota-Medeiros (Lisboa, Portugal)</i>